1	STATE OF MINNESOTA DISTRICT COURT							
2	COUNTY OF RAMSEY SECOND JUDICIAL DISTRICT							
3								
4	The State of Minnesota,							
5	by Hubert H. Humphrey, III,							
6	its attorney general,							
7	and							
8	Blue Cross and Blue Shield							
9	of Minnesota,							
10	Plaintiffs,							
11	vs. File No. C1-94-8565							
12	Philip Morris Incorporated, R.J.							
13	Reynolds Tobacco Company, Brown							
14	& Williamson Tobacco Corporation,							
15	B.A.T. Industries P.L.C., Lorillard							
16	Tobacco Company, The American							
17	Tobacco Company, Liggett Group, Inc.,							
18	The Council for Tobacco Research-U.S.A.,							
19	Inc., and The Tobacco Institute, Inc.,							
20	Defendants.							
21								
22	DEPOSITION OF M. LANCE REYNOLDS							
23								
24								
25								

1	(The following is the Rule 30.02(f)
2	Deposition of M. LANCE REYNOLDS, taken pursuant to
3	Notice of Taking Deposition, by videotape, at the
4	offices of Robins, Kaplan, Miller & Ciresi, Attorney
5	at Law, 2800 LaSalle Plaza, 800 LaSalle Avenue,
6	Minneapolis, Minnesota, on September 30, 1997,
7	commencing at approximately 2:06 o'clock p.m.)
8	
9	APPEARANCES:
10	On Behalf of the Plaintiffs:
11	Martha K. Wivell
12	Robins, Kaplan, Miller & Ciresi LLP
13	Attorneys at Law
14	2800 LaSalle Plaza
15	800 LaSalle Avenue
16	Minneapolis, Minnesota 55402
17	On Behalf of the Plaintiffs in the New York
18	State Actions:
19	Brian Stuart Campf
20	Goodkind Labaton Rudoff & Sucharow, LLP
21	Attorneys at Law
22	100 Park Avenue
23	New York, New York 10017
24	
25	

1	On Behalf of Philip Morris Incorporated:
2	Randall Frykberg
3	Dorsey & Whitney
4	Attorneys at Law
5	Pillsbury Center South
6	220 South Sixth Street
7	Minneapolis, Minnesota 55402-1498
8	
9	On Behalf of Brown & Williamson Tobacco
10	Corporation:
11	Steven D. McCormick
12	Kirkland & Ellis
13	Attorneys at Law
14	200 East Randolph Drive, 59th Floor
15	Chicago, Illinois 60601
16	
17	Jack M. Fribley
18	Faegre & Benson
19	Attorneys at Law
20	2200 Norwest Center
21	90 South 7th Street
22	Minneapolis, Minnesota 55402
23	
24	
25	

4

1	On Behalf of Lorilla:	rd Tobacco Company	:						
2	Howard A. Roston								
3	Doherty, Rumble	& Butler							
4	Attorneys at Law								
5	2800 Minnesota World Trade Center								
6	30 East Seventh Street								
7	St. Paul, Minnesota 55101-4999								
8									
9	On Behalf of B.A.T.	Industries P.L.C.:							
10	Michael S. Koma	r							
11	Simpson, Thacher & Bartlett								
12	Attorneys at Law								
13	425 Lexington Avenue								
14	New York, New York 10017-3954								
15									
16	EXAM	INATION INDEX							
17	WITNESS E	XAMINED BY	PAGE						
18	M. Lance Reynolds	Ms. Wivell	6,127,138						
19	j	Mr. McCormick	119,138						
20									
21									
22									
23									
24									
25									

5

1		EXHIBIT INDEX						
2	EXHIBIT	DESCRIPTION	PAGI					
3	(Plaintiffs')							
4	4454	Letter to Yeaman, 7/4/63, 68903 3420	18					
5	4455	Memo, Ward To Blott, 7/1/83, 67904	42					
6		0686 to 0692						
7	4456	"Receptors for Nicotine in the	45					
8		Central Nervous System:", 3/22/84,						
9		650000996 to 1034						
10	4457	"Note on Recommendations for future	76					
11		research interests given at the 2nd						
12		meeting of the Scientific Research						
13		Group - Montreal, August 6-8, 1986,"						
14		107356044 to 6047						
15	4458	Hawkins McCain & Blumenthal, Inc.,	136					
16		Conference Report, 7/28/77,						
17		777125397 to 5403/ BNW 23814 to 3820						
18								
19								
20								
21								
22								
23								
24								
25								

1	Ρ	R	0	С	Ε	Ε	D	Ι	N	G	S	

- 2 (Witness sworn.)
- M. LANCE REYNOLDS,
- 4 called as a witness, being first duly
- 5 sworn, was examined and testified as
- follows:
- 7 ADVERSE EXAMINATION
- 8 BY MS. WIVELL:
- 9 Q. Sir, would you please introduce yourself to the
- 10 ladies and gentlemen of the jury.
- 11 A. My name is Lance Reynolds.
- 12 Q. Mr. Reynolds, you and I have met before, haven't
- 13 we?
- 14 A. That's correct.
- 15 Q. I took your deposition in the case of Minnesota
- 16 -- State of Minnesota and Blue Cross\Blue Shield
- 17 versus the various cigarette manufacturers earlier
- 18 this year, didn't I?
- 19 A. Right.
- 20 Q. We spoke for two days, didn't we?
- 21 A. I believe so, yes.
- 22 Q. All right. Now sir, you are retired from Brown
- 23 & Williamson; right?
- 24 A. Yes.
- 25 Q. And before your retirement you had worked for

- 1 two cigarette manufacturers; isn't that true?
- 2 A. Yes.
- 3 Q. And you would agree that before you retired you
- 4 had spent the better part of your professional life
- 5 working for one or the other of those two cigarette
- 6 manufacturers; correct?
- 7 A. Most of it for Brown & Williamson.
- 8 Q. And sir, you would agree that you are now
- 9 retired; right?
- 10 A. Yes.
- 11 Q. Now when we last chatted, in addition to your
- 12 retirement benefits you were receiving money from
- 13 Brown & Williamson under a consulting contract;
- 14 right?
- 15 A. That's correct.
- 16 Q. Are you still receiving money under a consulting
- 17 contract with Brown & Williamson?
- 18 A. Yes.
- 19 Q. Now the contract that you and I spoke about last
- 20 time we met was from July 1st to July -- July 1st,
- 21 1996 to July 1st, 1997; right?
- 22 A. Right.
- 23 Q. And it's now September 30th, 1997. Do you have
- 24 a new contract?
- 25 A. The contract continued from year to year. In

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 fact I think actually it's a five-year contract,
- 2 expires in 2001.
- 3 Q. All right. Now sir, under the terms of that
- 4 contract you get paid \$75,000 per year for up to 60
- 5 days of work; right?
- 6 A. Right.
- 7 Q. That's 60 days per year.
- 8 A. Right.
- 9 Q. And you get paid that money whether you do
- 10 anything or not; right?
- 11 A. Right.
- 12 Q. So this year you are entitled again, under the
- 13 terms of the contract, to \$75,000; right?
- 14 A. Right.
- 15 Q. And you get that whether you work for Brown &
- 16 Williamson a single day or not.
- 17 A. Right.
- 18 Q. Now how many days have you worked for Brown &
- 19 Williamson since the first of July of this year?
- 20 A. About three or four.
- 21 Q. All right. Now sir, if you work beyond 60 days,
- 22 according to this contract, you get \$1,250 per day;
- 23 right?
- 24 A. Right.
- 25 Q. Now how many days did you work in -- beyond the

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 60 days in 1996/97?
- 2 A. About 25 or 30.
- 3 Q. All right. So if we were to figure the amount
- 4 that you received in your consulting contract last
- 5 year from Brown & Williamson, it would have been
- 6 \$75,000, and in addition \$1,250 per day times either
- 7 20 or 30; right?
- 8 A. Right.
- 9 Q. Now sir, that's in addition to your retirement
- 10 benefits; right?
- 11 A. Right.
- 12 Q. Now you understand that today you're here as
- 13 Brown & Williamson's spokesperson to testify on
- 14 behalf of the company; right?
- 15 A. Correct.
- 16 Q. Okay. And you're here because plaintiffs noted
- 17 the deposition of Brown & Williamson and asked the
- 18 company to produce a person to testify about matters
- 19 known or reasonably knowable to Brown & Williamson on
- 20 the subject of addiction and the control of nicotine
- 21 and other reinforcing substances in cigarettes, and
- 22 the design and manufacture of cigarettes; right?
- 23 A. That's basically what I understood, yes.
- 24 Q. All right. And you're here to be that
- 25 spokesperson today, aren't you, sir?

- 1 A. Yes.
- 2 Q. And you've agreed to be Brown & Williamson's
- 3 spokesperson on those issues.
- 4 A. Yes.
- 5 Q. And you have authority to speak on behalf of
- 6 Brown & Williamson concerning those issues; right?
- 7 A. Right.
- 8 Q. I'd like to turn to the subject of addiction
- 9 first, sir. That's not a subject on which you have
- 10 particular professional expertise personally, is it?
- 11 A. I'm not a psychiatrist, no.
- 12 Q. You're not a psychologist either, are you, sir?
- 13 A. No.
- 14 Q. All right. But you are aware that Brown &
- 15 Williamson has, to the public, denied that cigarette
- 16 smoking is addictive; right?
- 17 A. Yes, if you define "addiction" as classically
- 18 defined.
- 19 Q. Well sir, let's choose the words Brown &
- 20 Williamson has used. Brown & Williamson has said
- 21 cigarette smoking is not addictive under the
- 22 standards set forth by the 1964 surgeon general's
- 23 report; right?
- 24 A. Right.
- 25 Q. Brown & Williamson said that in a press release

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 that you've seen; isn't that true?
- 2 A. I don't know dispute it. I can't bring it to
- 3 mind right now but --
- 4 Q. All right. Well sir, showing you what's
- 5 previously been marked as Plaintiffs' Exhibit 4415,
- 6 this is a press release which Brown & Williamson
- 7 issued to the public in 1994; isn't it, sir?
- 8 MR. McCORMICK: Thank you.
- 9 A. Give me a second and, yes, it's a Brown &
- 10 Williamson 1994 press release.
- 11 Q. Now in that press release it says, "It has
- 12 always been B&W's position," that's Brown &
- 13 Williamson; right?
- 14 A. Right.
- 15 Q. And it goes on to say, "It has always been B&W's
- 16 position, and still is, that cigarette smoking is not
- 17 addictive under the standards set forth in the 1964
- 18 surgeon general's report"; right?
- 19 A. Right.
- 20 Q. And you would agree that one of the reasons
- 21 Brown & Williamson issued this press release is so
- 22 that people would hear it and believe what Brown &
- 23 Williamson was saying there; right?
- 24 A. I don't know the -- the circumstances of this
- 25 press release. I certainly agree with the sentence

- 1 we've just quoted that cigarette smoking is not
- 2 addictive under the standards set forth in the 1964
- 3 surgeon general's report.
- 4 Q. Now sir, you would agree that in later surgeon
- 5 general's report -- reports, the scientists who put
- 6 those reports together determined that cigarette
- 7 smoking was addictive; isn't that true?
- 8 A. Well I think it would be more accurate to say
- 9 that the addiction was redefined in a later surgeon
- 10 general's report so that cigarette smoking could be
- 11 included under that definition of addiction.
- 12 Q. Now sir, are you aware of the fact that even
- 13 before the 1964 surgeon general's report was issued,
- 14 that Brown & Williamson had in its possession
- 15 scientific research more extensive than that was --
- 16 which was available in the published scientific
- 17 literature concerning whether cigarette smoking was
- 18 addictive?
- 19 A. You've asked me a lot of questions all in one
- 20 piece then, but if I understand your question to me,
- 21 and I'm trying to rephrase it, you asked me if Brown
- 22 & Williamson had documents showing that cigarette
- 23 smoking was addictive under what definition?
- 24 Q. Well sir, isn't it true that Brown & Williamson
- 25 had in its possession, before the 1964 surgeon

- 1 general's report, scientific research more extensive
- 2 than that which was available in the published
- 3 scientific literature which showed that cigarette
- 4 smoking was addictive?
- 5 A. Well I'm going to say "no" to that.
- 6 Q. All right. Well let me show you what's
- 7 previously been marked in this litigation as
- 8 Plaintiffs' Exhibit 514. This is a document Bates
- 9 numbered 301083820; right?
- 10 A. Yes.
- 11 Q. And it is entitled "PRIVATE & CONFIDENTIAL" and
- 12 dated 13th February, 1962; correct?
- 13 A. Correct.
- 14 Q. And the subject heading is "THE EFFECTS OF
- 15 SMOKING, PROPOSAL FOR FURTHER RESEARCH CONTRACTS WITH
- 16 BATTELLE"; right?
- 17 A. Right.
- 18 Q. You've read this document, sir, haven't you?
- 19 A. Yes.
- 20 Q. And sir, you would agree that it summarizes
- 21 research that British-American Tobacco Company had
- 22 contracted to be done with Battelle Institute in
- 23 Germany.
- 24 A. Geneva, I believe.
- 25 Q. I'm sorry, that's right. Let me rephrase the

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 question.
- 2 You would agree that Exhibit 514 summarizes
- 3 research British-American Tobacco Company had
- 4 contracted to be done with Battelle Institute in
- 5 Geneva, Switzerland; right?
- 6 A. I certainly agree it's a document about research
- 7 that -- which American Tobacco was undertaking with
- 8 Battelle in Geneva. I'm -- Off the top of my head,
- 9 till I've looked at it some more, I'm not quite sure
- 10 whether it's a summary, a budget request or exactly
- 11 what it is, but it's a document concerning research
- 12 with Battelle.
- 13 Q. All right. And we know from the first paragraph
- 14 on the first page that it references research
- 15 contracts with Battelle that started in February of
- 16 1959; right?
- 17 A. Yes.
- 18 Q. And according to the first paragraph of Exhibit
- 19 514, the overall objective was to increase
- 20 British-American Tobacco's knowledge of the
- 21 psychological and physiological effects of smoking
- 22 and to explore the possibilities of obtaining the
- 23 same results by a device other than a cigarette;
- 24 right?
- 25 A. Right.

- 1 Q. Now if we turn to the page that ends with Bates
- 2 number 828. At the top of the page is a statement,
- 3 "As a result of these various researches we now
- 4 possess a knowledge of the effects of nicotine far
- 5 more extensive than exists in published scientific
- 6 literature"; correct?
- 7 A. That is what the document says. I take that as
- 8 hyperbole from the earth author. I think there was
- 9 as much, if not more, in the scientific literature
- 10 than was developed out of this research.
- 11 Q. Sir, this document was issue -- or was written
- 12 by Sir Charles Ellis, wasn't it?
- 13 A. That's the author, yes.
- 14 Q. Have you ever spoken with Sir Charles Ellis
- 15 about Exhibit 514?
- 16 A. I only met Sir Charles Ellis once in my life,
- 17 and it was not to discuss this exhibit, no.
- 18 Q. All right. And so you don't know whether what
- 19 he was saying was accurate or hyperbole, do you, sir?
- 20 A. Oh, I do. I mean you just look at the
- 21 scientific literature and -- the extant scientific
- 22 literature at the time, and there's a lot more in
- 23 that than there is in this.
- 24 Q. Well sir, there may be a whole lot more, but you
- 25 would agree that British-American Tobacco Company

- 1 possessed information that was not published in the
- 2 scientific literature concerning whether cigarette
- 3 smoking was addictive; right?
- 4 A. Well let's back up. Can you just ask me that
- 5 question again?
- 6 Q. Yes, sir.
- Well there may be a whole lot more, but you
- 8 would agree that British-American Tobacco Company
- 9 possessed information that was not published in the
- 10 scientific literature concerning whether cigarette
- 11 smoking was addictive.
- 12 A. No, I don't agree with that.
- 13 Q. Well sir, this particular document references
- 14 research entitled "The Fate of Nicotine in the
- 15 Body." That was never published in the scientific
- 16 literature, was it, sir?
- 17 A. There's tons of stuff in the scientific
- 18 literature on nicotine in the body.
- 19 MR. McCORMICK: Could you please let him
- 20 finish?
- 21 Q. Sir, was the document entitled "The Fate of
- 22 Nicotine in the Body" ever published in the
- 23 scientific literature?
- MR. McCORMICK: Excuse me. I want to
- 25 object to your interruption of the witness' last

- 1 answer, ask you to please let him finish his answer
- 2 to your question.
- 3 A. The Battelle study was not published in the
- 4 scientific literature.
- 5 Q. In fact none of the Battelle studies that are
- 6 referenced in this report that were done as part of
- 7 project HIPPO or project MAD HATTER were ever
- 8 published in the scientific literature, were they,
- 9 sir?
- 10 A. No, it's very unlikely that they would have
- 11 passed peer review.
- 12 Q. Well sir, they were never submitted for peer
- 13 review, were they?
- 14 A. Well because they were not in a -- a state to be
- 15 submitted for peer review.
- 16 Q. Sir, they were never submitted for peer review,
- 17 were they?
- 18 A. No, because they weren't ready to be. There
- 19 wasn't -- This work wasn't good enough.
- 20 Q. Well sir, is there a single document that you
- 21 can direct me to that says this work wasn't good
- 22 enough?
- 23 A. Sure.
- 24 Q. Which document is that, sir?
- 25 A. Dr. Armitage from the Tobacco Research Council

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 in Harrogate visited Geneva and reviewed the work
- 2 that had been done and wrote fairly scathing
- 3 criticism of it.
- 4 Q. Actually what he suggested was that it shouldn't
- 5 be given to the surgeon general of the United States
- 6 in preparation for the surgeon general's 1964
- 7 report. Isn't that true, sir?
- 8 A. I don't know whether he did or not. What I do
- 9 remember -- You asked me a specific question about
- 10 whether Armitage thought this stuff was good enough
- 11 for publication, and he said no, he had all sorts of
- 12 questions about it.
- 13 Q. Well sir, isn't it true that Dr. Armitage
- 14 advised that it was too early to submit the Battelle
- 15 reports to the surgeon general's committee and that
- 16 as a result of that they were not shared with the
- 17 surgeon general's committee when the 1964 report was
- 18 being prepared?
- 19 A. Well they weren't shared because they weren't
- 20 good enough.
- 21 Q. Well sir, let me show you a document and ask you
- 22 if it says that.
- 23 (Plaintiffs' Exhibit 4454 marked for
- identification.)
- 25 BY MS. WIVELL:

- 1 Q. Sir, showing you what's been marked as
- 2 Plaintiffs' Exhibit 4454, this is a letter to a
- 3 lawyer at Brown & Williamson from someone at
- 4 British-American Tobacco Company; right?
- 5 A. Yes.
- 6 Q. And sir, it advises that the scientific reports
- 7 that are referenced in Exhibit 514 not be shared with
- 8 the surgeon general's committee. Isn't that true?
- 9 A. Well what it says is "T.R.C. CONSULTANT
- 10 SCIENTISTS ADVISE IT IS TOO EARLY TO SUBMIT BATTELLE
- 11 REPORTS TO SURGEON GENERAL'S COMMITTEE..." And it
- 12 was too early because the work was embryo,
- 13 inconclusive.
- 14 Q. Sir, you didn't read the whole rest of the
- 15 sentence, did you? It goes on to say, "BUT WE THINK
- 16 THEY WILL AGREE THAT CONTINUATION BY BATTELLE OF THE
- 17 WORK WOULD BE USEFUL"; right?
- 18 A. Well it might be.
- 19 Q. All right, sir. And you would agree that in --
- 20 nowhere in this document does it say that the work
- 21 that Battelle did that looked at the psychological
- 22 and physiological effects of smoking on the body was
- 23 bad work or bad science; right?
- 24 A. No. If I gave you that impression, I didn't
- 25 mean to. I just said it was inconclusive and

- 1 Armitage had some pretty severe criticisms of it.
- 2 Q. Well sir, turning back to Exhibit 514, Sir
- 3 Charles Ellis concluded that smoking is addictive
- 4 based on this research, didn't he?
- 5 A. Well let's first draw my attention to the page
- 6 that you want me to look at, then we'll talk about
- 7 addiction. So where are we?
- 8 Q. Well sir, let's start by looking at the page
- 9 that ends with Bates number 826. There Sir Charles
- 10 said, in the middle of the first paragraph, "However,
- 11 the force of the habit or the strength of addiction
- 12 is not such as to give any grounds for complacency in
- 13 the face of alternative methods of stimulating the
- 14 body to meet stress, and that is just where the
- 15 danger lies since alternative methods are becoming
- 16 available"; correct?
- 17 A. That's what Sir Charles wrote in that paragraph,
- 18 yes.
- 19 Q. And then he goes on to say, at the bottom, in
- 20 the bottom paragraph, "What we need to know above all
- 21 things is what constitutes the hold of smoking, that
- 22 is, to understand addiction"; right?
- 23 A. Yeah. Now I don't know, and you don't know, and
- 24 who does know how Sir Charles was defining
- 25 "addiction" because I'm not aware that he's defined

- 1 it.
- 2 Q. Well sir, if we turn to the end of page 830 we
- 3 see he again references addiction, doesn't he, sir?
- 4 A. Well he references addiction, yes.
- 5 Q. And he says, "Thus we have already greatly
- 6 increased our knowledge of the manifold ways in which
- 7 nicotine affects the body and, in particular, have
- 8 identified and studied separately the stress
- 9 resisting mechanism and the other effect on the liver
- 10 which we believe is responsible for addiction." Have
- 11 I read that correctly, sir?
- 12 A. You have read correctly what he stated. I think
- 13 there are problems in here both of science and
- 14 definition.
- 15 Q. Well sir, Brown & Williamson never shared with
- 16 the public that its sister company, British-American
- 17 Tobacco, employed a person who believed cigarette
- 18 smoking was addictive, did it?
- 19 MR. KOMAR: Object to form.
- 20 (Interruption by the reporter.)
- 21 A. I'm sorry, could you repeat the question?
- 22 Q. Yes, sir. Brown & Williamson never shared with
- 23 the public that its sister company, British-American
- 24 Tobacco, employed a person who believed that
- 25 cigarette smoking was addictive, did it?

- 1 A. Well I -- it's such a peculiar question, I don't
- 2 even know how to begin answering it. I mean, there
- 3 may very well have been people who believed it. Who
- 4 knows, there are loads of scientists.
- 5 But, you know, to be real accurate, I don't know
- 6 whether you consider a consultant an employee or
- 7 not. If you want to define a consultant as an
- 8 employee, and then you can define how Sir Charles
- 9 defined addiction, then with those -- those provisos,
- 10 but, I mean, it's such a weird question to ask.
- 11 As I say, I'm sorry, I don't really know how to
- 12 answer it.
- 13 Q. Well Sir Charles was on the board of
- 14 British-American Tobacco Company, wasn't he; the
- 15 Board of Directors?
- 16 A. I don't know.
- 17 O. You just don't know one way or the other?
- 18 (Interruption by the reporter.)
- 19 A. No.
- 20 Q. Now sir, you understand that Sir Charles also
- 21 met with researchers to discuss with them the issue
- 22 of whether cigarette smoking was addictive; right?
- 23 A. Yeah, I think if we can say that he met with
- 24 people to try and understand why people smoked and
- 25 smoking behavior and that's -- if we don't keep on

- 1 getting hung up on "addiction" for the moment but
- 2 just met with people to discuss why people smoked,
- 3 sure.
- 4 Q. And as a matter of fact, he wrote memos that
- 5 found their way into Brown & Williamson's files that
- 6 talked about the cravings which smokers experience
- 7 when nicotine withdrawal begins; isn't that true?
- 8 A. If you showed me the document, if it's in the
- 9 files, and then I probably will agree with you.
- 10 Q. All right, sir. We're going to have to mark my
- 11 copy because I ended up with only one.
- 12 (Discussion off the stenographic record.)
- 13 BY MS. WIVELL:
- 14 Q. Showing you what's previously been marked as
- 15 Plaintiffs' Exhibit 552, that is a document which is
- 16 a report of a meeting which Mr. Ellis -- which Sir
- 17 Charles Ellis had with two scientists from Battelle
- 18 Geneva; right?
- 19 A. Right. Well I don't know if it's a report of a
- 20 meeting, it's -- it's -- this says "A TENTATIVE
- 21 HYPOTHESIS ON NICOTINE ADDICTION, " for the
- 22 British-American Tobacco Company, by Kaselbach and
- 23 Libert. I don't know whether it's a meeting report
- 24 or not.
- 25 Q. All right, sir. For the record, this document

- 1 is Bates numbered 536480912 on its first page; right?
- 2 A. Right.
- 3 Q. All right. Would you turn to the second page of
- 4 the document. I have highlighted a portion of the
- 5 first paragraph; correct?
- 6 A. Yes.
- 7 Q. Would you please read to the ladies and
- 8 gentlemen of the jury what's written in that report?
- 9 A. Okay. And this report is this tentative
- 10 hypothesis by these two Battelle employees. And it
- 11 says, on page 2, "If nicotine intake, however, is
- 12 prohibited to chronic smokers, the
- 13 corticotropin-releasing ability of the hypothalamus
- 14 is greatly reduced, so that these individuals are
- 15 left with an unbalanced endocrine system. A body
- 16 left in this unbalanced status craves for renewed
- 17 drug intake in order to restore the physiological
- 18 equilibrium. This "uneasiness "desire explains the
- 19 addiction of the individual to nicotine."
- 20 Q. Doesn't it say, "this unconscious desire
- 21 explains the addiction of the individual to
- 22 nicotine"?
- 23 A. That's what it said. Sorry, what did I say?
- 24 Q. I'm sorry, I thought you said something else.
- 25 A. Well I may have done. It's kind of small and

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 squidgy writing.
- 2 Q. All right. Now sir, you understand that these
- 3 documents that we have looked at so far, the one that
- 4 you have in your hand, Exhibit 552, plus the others
- 5 concerning the research that was done at Battelle,
- 6 were sent by British-American Tobacco to Brown &
- 7 Williamson; right?
- 8 A. I believe that's correct, yes.
- 9 Q. Now sir, you understand that Brown & Williamson
- 10 also had information in its files that showed that
- 11 cigarette smokers went through withdrawal when they
- 12 were not able to have a cigarette on a regular
- 13 basis.
- 14 A. Well there's a huge amount of anecdotal evidence
- 15 about withdrawal from cigarettes, and that's not only
- 16 part of everyday experience, I guess, I mean, it's
- 17 everywhere. It doesn't happen to be just in Brown &
- 18 Williamson files. I would assume it's in novels,
- 19 newspapers, anywhere.
- 20 Q. Well are you admitting that cigarette smokers go
- 21 through withdrawal when they can't get their
- 22 cigarettes on a regular basis?
- 23 A. Well depends how you define "withdrawal," but as
- 24 an ex smoker myself, I might have been a little
- 25 grumpy if I didn't have a cigarette, might have had a

- 1 funny taste in my mouth. If you -- If you consider
- 2 that withdrawal, sure.
- 3 Q. All right. Well sir, and it's true, isn't it,
- 4 that Brown & Williamson had evidence in its files
- 5 that cigarette smokers who did not get their normal
- 6 regular cigarette dose of nicotine went through
- 7 withdrawal.
- 8 A. Well, as I say, if you define "withdrawal" as
- 9 I've defined it, you know, I'm not sure of any sort
- 10 of questionnaire stuff but it's just sort of general
- 11 knowledge that smokers report various kinds of mild
- 12 physical/psychological discomfort when either they
- 13 don't have a cigarette for a long time or are giving
- 14 up smoking.
- 15 Q. Sir, I'm going to show you what's previously
- 16 been marked as Plaintiffs' Exhibit 755. This is a
- 17 document from Brown & Williamson's files, isn't it?
- 18 A. Well it's so jolly hard even to read that I
- 19 don't know whether it's from our files or not. If it
- 20 is, I mean, I'll sure accept it.
- 21 Q. Well sir, did you read this document in
- 22 preparation for your deposition today?
- 23 A. Well, I kind of looked at it very briefly this
- 24 morning, but I was put off by the quality of the copy
- 25 so I -- I didn't study it in any detail.

- 1 Q. All right. Well sir, directing your attention
- 2 to the first two paragraphs of the document, those
- 3 paragraphs tell us essentially that this particular
- 4 document is a summary of excerpts from an R&D report
- 5 entitled "Why Do People Smoke."
- 6 A. Umm-hmm.
- 7 Q. A smoking behavior motives and incentives paper,
- 8 and notes on a St. Martin Island conference that
- 9 I. W. Hughes attended; correct?
- 10 A. Yeah.
- 11 Q. Now let's start with I. W. Hughes. Wally Hughes
- 12 was vice-president of research and development for
- 13 Brown & Williamson and then went on to become
- 14 president of the company, didn't he?
- 15 A. And subsequently chairman, yes.
- 16 Q. And sir, you are aware of notes that were taken
- 17 at a St. Martin Island conference in which smoking
- 18 and the addictive nature of smoking was discussed,
- 19 aren't you?
- 20 A. Well again, you asked me several questions at
- 21 once. This St. Martin Island conference was actually
- 22 published as a book, "Smoking Behavior: Motives
- 23 and --
- 24 (Interruption by the reporter.)
- 25 A. -- Incentives," I think that's what it was

- 1 called.
- 2 Edited by Durn, and this was -- you know, this
- 3 is a book you can go and get from your public library
- 4 or go and buy in a book store. I don't remember
- 5 specifically seeing notes by Hughes on the subject,
- 6 but as I say, the book I still have.
- 7 Q. All right. You've read it, sir, haven't you?
- 8 A. Yeah.
- 9 Q. All right. Now this paper basically is a
- 10 synopsis of information taken from those three
- 11 sources that we've just discussed; right?
- 12 A. That's what it says.
- 13 Q. And sir, if you turn to the second page, it says
- 14 there, "Nicotine vacates the system in 30 minutes or
- 15 so and at that time withdrawal starts"; right?
- 16 A. Sorry, where does it say that? Okay.
- 17 Q. Do you see the end of the first paragraph?
- 18 A. I see it says that. I'm not sure that I would
- 19 -- Well it certainly doesn't vacate the system in 30
- 20 minutes, the nicotine -- half life of nicotine in the
- 21 body is very much longer, so I don't know where
- 22 that's drawn from.
- 23 Q. All right. But it does go to say -- go on to
- 24 say, "Nicotine vacates the system in 30 minutes or so
- 25 and at that time withdrawal starts", doesn't it?

- 1 A. Well that's what it says. I don't agree with
- 2 it.
- 3 Q. All right. Well but that's at least what this
- 4 document out of Brown & Williamson's files concludes;
- 5 right?
- 6 A. I don't know whether it concludes it. It says
- 7 it.
- 8 Q. It also talks about addicted smokers, doesn't
- 9 it, sir?
- 10 A. Well I don't know. Where -- Guide me.
- 11 Q. All right. Can you turn to the page that ends
- 12 with Bates number 106. There is a heading there that
- 13 says, "Addictive" smokers -- "Smoking"; right?
- 14 A. Oh, you're referring to Tomkins' theory which I
- 15 guess starts on Bates page 104, and this is -- this
- 16 section of this document is describing Tomkins'
- 17 theory of smoking motivation and he has various kinds
- 18 of smoking motivation; habitual smoking,
- 19 positive-effect smoking, negative-effect smoking and
- 20 addictive smoking, so they are describing here
- 21 Tomkins' theory.
- 22 Q. All right. And a little earlier in the document
- 23 there is reference to a Dr. Russell who was, I
- 24 believe, a consultant to British-American Tobacco
- 25 Company; right?

- 1 A. I don't know if he ever was actually a
- 2 consultant. He certainly advised and worked with
- 3 British-American Tobacco. As you are probably aware,
- 4 he was sort of one of the leading British smoking
- 5 researchers and antismokers.
- 6 Q. Well didn't you tell me at our last meeting,
- 7 sir, during the deposition, that Dr. Russell was a
- 8 consultant to British-American Tobacco?
- 9 A. I don't know whether I did or I didn't. As I
- 10 said, he certainly worked and advised with them on
- 11 some projects. Whether he actually accepted any
- 12 money from them, I have no idea.
- 13 Q. Now sir, Dr. Russell was of the opinion that
- 14 cigarette smoking was addictive, isn't that true?
- 15 A. Yes, he did think that.
- 16 Q. And as a matter of fact, he is quoted in this
- 17 document as commenting about the purpose of nicotine,
- 18 isn't he, sir?
- 19 A. Are we on page number 101?
- 20 Q. Well can you take a look at the page that ends
- 21 with 103. Do you see there in the middle of the
- 22 sentence -- or the middle of the page reference to
- 23 "According to Russell, to prove dependence on a drug
- 24 it is critical that its withdrawal leads to some
- 25 negative effects"?

- 1 A. I see that, yes.
- 2 Q. And it goes on to say, "Thus withdrawal of
- 3 cigarettes from heavy smokers may reduce them to a
- 4 subjectively distressed state, with symptoms of
- 5 anxiety, depression, irritability, restlessness,
- 6 intense craving as well as difficulty in
- 7 concentration"; right?
- 8 A. Right.
- 9 Q. Now sir, isn't it true that Brown & Williamson
- 10 recognized -- I'm sorry. Strike that.
- 11 Isn't it true that Brown & Williamson knew that
- 12 cigarette smokers were addictive -- addicted, and
- 13 that was an operating hypothesis within the company?
- 14 A. No, the definition of addiction which the
- 15 company accepts and subscribes to is basically the
- 16 one that includes an addictive substance produces
- 17 behavioral intoxication and the user will go to
- 18 extraordinarily-harmful-to-society lengths to obtain
- 19 the addictive substance. And so cigarette smoking,
- 20 by no stretch of the imagination, falls into that and
- 21 that's why Brown & Williamson doesn't consider
- 22 cigarette smoking addictive.
- 23 Q. Well sir, Brown & Williamson has access to
- 24 research documents and memos from its sister company,
- 25 British-American Tobacco, as a result of a pooling

- 1 agreement and cost-sharing agreement that it has with
- 2 BATCo; correct?
- 3 A. Correct.
- 4 Q. And in fact British-American Tobacco shared the
- 5 information that it obtained from Battelle Institute
- 6 with Brown & Williamson; isn't that true?
- 7 A. Yes.
- 8 Q. And Brown & Williamson also received copies of
- 9 memos which BATCo scientists had written concerning
- 10 the subject of addiction; right?
- 11 A. Yes.
- 12 Q. Sir, showing you what's previously been marked
- 13 as Plaintiffs' Exhibit 553, this is a memo that Brown
- 14 & Williamson would have had access to that was
- 15 written to Dr. S. J. Green and Dr. C. I. Ayres;
- 16 right?
- 17 MR. McCORMICK: Now wait a minute. Could
- 18 you ask those questions one at a time, please?
- 19 Q. Well this is a memo that Brown & Williamson
- 20 would have had access to that was written to Dr. S.
- 21 J. Green and Dr. C. I. Ayres; right?
- MR. McCORMICK: Object, compound.
- 23 A. Okay. The memo, as we've said, is sent to Green
- 24 and Ayres. Whether Brown & Williamson had a copy of
- 25 it or not, I just don't know. I mean, there isn't a

- 1 Brown & Williamson recipient shown.
- 2 Q. All right. But clearly Brown & Williamson had
- 3 the right to have access to any research or memos
- 4 written by scientists at BATCo; right?
- 5 A. In principle, yeah.
- 6 Q. All right. Now sir, for the record, Exhibit 553
- 7 is Bates numbered 105392360; right?
- 8 A. Right.
- 9 Q. Would you turn to the page that ends with Bates
- 10 number 366. This page shows that it -- the memo was
- 11 written by A. K. Comer; right?
- 12 A. Right.
- 13 Q. Now do you know who Ms. Comer was?
- 14 A. I met her on a number of occasions, yes.
- 15 Q. And what area did she work in at BATCo?
- 16 A. Broadly I would call it the area of smoking
- 17 behavior.
- 18 Q. She was a psychologist, wasn't she?
- 19 A. I don't know.
- 20 Q. Now she reports in this memorandum, Exhibit 553,
- 21 on comments of a talk that she had attended that had
- 22 been given by Dr. Russell.
- 23 A. Yes.
- 24 Q. And she says, after reading -- I'm sorry. She
- 25 says at -- toward the end of this document, "In

- 1 summary, it appears that most workers who are not
- 2 directly concerned with the tobacco industry use the
- 3 terms 'addiction' or 'dependence' rather than
- 4 'habituation', and can be considered quite correct
- 5 in doing so"; right?
- 6 A. Considered quite correct from their point of
- 7 view, yes.
- 8 Q. And this is the point of view of a scientist at
- 9 BATCo who's involved with smoker psychology; right?
- 10 A. Well I don't -- don't read the paragraph quite
- 11 the same way as you do. She's saying that workers
- 12 who were not directly concerned with tobacco industry
- 13 used the terms addiction or dependence rather than
- 14 habituation, and they, in their opinion, have a case
- 15 for doing that.
- 16 And as an objective person she's saying I can
- 17 see their point of view, but that's not necessarily
- 18 our point of view.
- 19 Q. Well this document also quotes -- I'm sorry.
- 20 Strike that.
- 21 You're aware that Dr. Russell was of the opinion
- 22 that cigarette smoking was addictive; correct?
- 23 A. Yes, yes.
- 24 Q. Now are you also aware -- Strike that.
- Do you know who Dr. M. Oldman is?

- 1 A. Yeah, he was a B.A.T. employee at one time who
- 2 was also a psychologist.
- 3 Q. All right. And he also worked in the area of
- 4 smoker motivation and dependency for BATCo, didn't
- 5 he?
- 6 A. Well, he worked largely in the area of, if I
- 7 recollect it correctly, in subjective assessment,
- 8 trying to find out and get panels to describe what
- 9 cigarettes taste like. He may have done some work on
- 10 smoking behavior as well.
- 11 Q. Sir, have you reviewed memos that Dr. Oldman has
- 12 written on the issue of why people smoke?
- 13 A. Not in connection with this deposition, no.
- 14 Q. Sir, showing you what's previously been marked
- 15 as Plaintiffs' Exhibit 611, this is a document that
- 16 begins with the Bates number 105392223; correct?
- 17 A. Yes.
- 18 Q. And this is a memo written by Dr. Oldman to Dr.
- 19 Green.
- MR. McCORMICK: Excuse me. What's the
- 21 exhibit number again on this?
- 22 MS. WIVELL: 611.
- MR. McCORMICK: Thank you.
- 24 Q. Sir, this is a memo written by Dr. Oldman to Dr.
- 25 Green at BATCo; right?

- 1 A. Right.
- 2 Q. And the date of the document is November 25th,
- 3 1977.
- 4 A. Right.
- 5 Q. And he refers to the fact, in the first page,
- 6 that he is enclosing a note entitled "Smoking
- 7 Motivation and Dependency"; right?
- 8 A. Right.
- 9 Q. And if we turn to the second page of Exhibit 611
- 10 we see the beginning of that note; right?
- 11 A. Yeah.
- 12 Q. Now he's talking about the smoker population in
- 13 this note entitled Smoker Motivation and Dependency;
- 14 right?
- 15 A. Right.
- 16 Q. And the last paragraph -- I'm sorry. Strike
- 17 that.
- 18 The last sentence of the first page talks about
- 19 the motivation of the smoker; right?
- 20 A. I'm sorry, I've never seen this -- not that I've
- 21 never seen it before, I haven't seen it recently, so
- 22 I'm trying to catch up. Sorry. And your question?
- 23 Q. Yes, sir. Let me restate it.
- In the last sentence of the page he's talking
- 25 about smoker motivation; right?

- 1 A. Well he's talking about smoker motivation in the
- 2 whole paragraph and he's saying there might be a
- 3 continuum of reasons why smokers smoke.
- 4 Q. And he's talking about, in the last sentence,
- 5 "the latter motivation," as he puts it; correct?
- 6 A. Yes.
- 7 Q. And he says, "The latter motivation, however,
- 8 more closely resembles an urge or drive and might be
- 9 described as an addictive behavior beyond cognitive
- 10 control and likely to be associated with
- 11 pharmacological dependency"; right?
- 12 A. Right. I mean, he's setting up a hypothesis
- 13 here. This isn't factual stuff. This is saying,
- 14 let's take a theory and we can see smokers'
- 15 motivations running from one extreme to another, and
- 16 these are the two ends of the scale.
- 17 Q. And "addiction" is on the one end of the scale,
- 18 according to Dr. Oldman; right?
- 19 A. Well an addictive behavior. However, he's --
- 20 well he does define that in part but, you know, I'd
- 21 refer you back to the cover page as well where he
- 22 says, "...this note contains a number of possibly
- 23 dubious assumptions" and "it may be that the implied
- 24 research proposals are premature." I think in fact
- 25 what he says is I'm trying to stimulate some

- 1 discussion here.
- 2 Q. And he's talking then about giving the broadest
- 3 consideration to the topic so that it can be
- 4 discussed outright; right?
- 5 A. That seems to be it, yes.
- 6 Q. Now sir, isn't it true that approximately the
- 7 same time that Dr. Oldman was talking about smoker
- 8 motivation in terms of addiction, folks at Brown &
- 9 Williamson were also internally recognizing that
- 10 smoking was addictive?
- 11 A. No. I mean, we keep on getting muddled up how
- 12 I'm defining "addiction" and how you're defining
- 13 "addiction," and we never have considered smoking
- 14 addictive at Brown & Williamson.
- 15 Q. Well sir, let me show you --
- 16 A. I don't know on behalf of B.A.T. either except,
- 17 you know, in a very loose use and undefined way of
- 18 using the word.
- 19 Q. Sir, show -- let me show you what's previously
- 20 been marked as Plaintiffs' Exhibit 178. This is an
- 21 internal Brown & Williamson document from one Brown &
- 22 Williamson employee to another, isn't it, sir?
- 23 A. It's from one junior marketing person to another
- 24 junior marketing person, yeah.
- 25 Q. And they're both Brown & Williamson employees,

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 aren't they; sir?
- 2 A. They were.
- 3 Q. At the time this memo was written.
- 4 A. Yes.
- 5 Q. And it's entitled "Future Consumer Reaction To
- 6 Nicotine"; right?
- 7 A. Right.
- 8 Q. And it says in the second paragraph, "Very few
- 9 consumers are aware of the affects of nicotine, i.e.,
- 10 its addictive nature and that nicotine is a poison";
- 11 right?
- 12 A. Well the --
- 13 Q. That's what it says sir, doesn't it?
- 14 A. What it says is just what you read out to me,
- 15 and "its addictive nature" is plain flat wrong, and
- 16 "nicotine is a poison," as we discussed when I was
- 17 last here, is well known to both you, me and the
- 18 State of Minnesota.
- 19 Q. Well sir, you would agree that very few
- 20 consumers were aware of the fact that nicotine was
- 21 addictive.
- 22 A. Nicotine isn't addictive.
- 23 Q. And so, sir, if a smoker heard you say that or
- 24 read -- We'll start with you.
- 25 If a smoker heard you say that, would it be

- 1 reasonable for them to believe what you're telling
- 2 them is the truth?
- 3 A. They would ask me to justify why, and I would
- 4 tell them.
- 5 Q. Well sir, I'm not sure that answers my
- 6 question.
- 7 A. Absolute --
- 8 Q. Would it be -- I'm sorry.
- 9 You know the rules. You can't talk when I'm
- 10 talking and vice versa; right?
- 11 A. Right.
- 12 Q. Would it be reasonable for a person who heard
- 13 you deny that smoking was addictive, to believe
- 14 that?
- MR. McCORMICK: Objection, mischaracterizes
- 16 the statement.
- 17 A. Yeah.
- 18 Q. Okay. Now sir, if a person read Brown &
- 19 Williamson's press release that claimed that smoking
- 20 was not addictive under the standards set forth in
- 21 the 1964 surgeon general's report, it would be
- 22 reasonable for that person to believe Brown &
- 23 Williamson, wouldn't it?
- 24 A. Well we're talking about two different things.
- 25 We were talking in this about nicotine being

- 1 addictive and I've -- Is that subject now closed?
- 2 Are we moving on to another subject?
- 3 Q. I'm sorry, I don't think you've answered my
- 4 question, sir. Let me repeat it again.
- If a person read Brown & Williamson's press
- 6 release that claimed that cigarette smoking wasn't
- 7 addictive under the standards set forth in the 1964
- 8 surgeon general's report, it would be appropriate for
- 9 Brow -- for that person to believe that Brown &
- 10 Williamson was telling them the truth; isn't that
- 11 true?
- 12 A. It would be appropriate, yes.
- 13 Q. All right. Now sir, you know that Brown &
- 14 Williamson employees used -- I'm sorry. Strike
- 15 that.
- 16 You know that Brown & Williamson employees
- 17 typically referred to smoking as an addictive
- 18 behavior, don't you?
- 19 A. No, I don't.
- 20 Q. Sir, showing you what's previously been marked
- 21 as Plaintiffs' Exhibit 452, this is a document from
- 22 one Brown & Williamson personnel to a number of other
- 23 Brown & Williamson employees; correct?
- 24 A. All long gone.
- 25 Q. All right. But all Brown & Williamson

- 1 employees, weren't they?
- 2 A. All marketing people.
- 3 Q. Nonetheless, they were Brown & Williamson
- 4 employees; right?
- 5 A. Correct.
- 6 Q. And if we turn to the second page of the
- 7 document, this document begins with point 1,
- 8 "Relationship of nicotine level to switching
- 9 behavior"; right?
- 10 A. Right.
- 11 Q. And it says, "Nicotine is the addicting agent in
- 12 cigarettes, doesn't it, sir?
- 13 A. That's what Mr. Mellman said, yes.
- 14 Q. And sir, isn't it true that Brown & Williamson
- 15 employees often referred to the fact internally that
- 16 cigarette smokers of their products were addicted to
- 17 cigarette smoking?
- 18 A. No.
- 19 (Plaintiffs' Exhibit 4455 marked for
- identification.)
- 21 BY MS. WIVELL:
- 22 Q. Sir, showing you what's been marked as
- 23 Plaintiffs' Exhibit 4455, this is a document that
- 24 begins with the Bates number 679040686; correct?
- 25 A. Yes.

- 1 Q. And this is a document written in 1983 from one
- 2 Brown & Williamson employee to another -- to a number
- 3 of other Brown & Williamson employees; correct?
- 4 A. From a Brown & Williamson marketing person to a
- 5 number of other Brown & Williamson marketing
- 6 persons.
- 7 Q. And it's entitled --
- 8 But they're all -- whether or not they're in the
- 9 marketing department, they were Brown & Williamson
- 10 employees, weren't they, sir?
- 11 A. Well except for the two on the right who, Hannum
- 12 and something or other, Mavers, who have a
- 13 parenthesis C&W.
- 14 Q. Which stands for what, sir?
- 15 A. Well I can speculate to the point that that was
- 16 some external supplier, but I don't know who.
- 17 Q. And the subject of this is "RALEIGH/BELAIR
- 18 COUPON STRATEGY"; correct?
- 19 A. Yes.
- 20 Q. And if we turn to the second page of the
- 21 document, do you see reference to Raleigh and Belair
- 22 or R and B smokers being addicted?
- 23 A. That's what this document says, yes.
- 24 Q. It says specifically, "Raleigh and Belair
- 25 smokers are addicted to smoking"; right?

- 1 A. That's apparently the author -- what the author
- 2 is saying here. It's his viewpoint.
- 3 Q. Now sir, let me ask you again.
- 4 Isn't it true that Brown & Williamson employees
- 5 commonly referred to the fact internally that
- 6 cigarette smoking was addictive?
- 7 A. No, I mean, you produced three documents out of
- 8 I don't know how many you have, of like 33 million,
- 9 I'm quite sure you can produce another 30 or 40 but,
- 10 you know, as someone who was there working at Brown &
- 11 Williamson every day for 23 years, no, we did not
- 12 commonly talk about cigarette smoking being addictive
- 13 or Raleigh and Belair smokers being addicted to
- 14 smoking.
- 15 Q. Well sir, you were aware that Brown & Williamson
- 16 had in its possession information that showed
- 17 nicotine had an effect on the brain; right?
- 18 A. Yeah.
- 19 Q. And you understand that Brown & Williamson had
- 20 information that confirmed the existence of specific
- 21 binding sites in the brain -- I'm sorry -- in the
- 22 central nervous system for nicotine; right?
- 23 A. Well golly, that's been known for eons.
- 24 Q. Well sir, we're talking about Brown & Williamson
- 25 here. You would agree that Brown & Williamson had

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 scientific research which confirmed the existence of
- 2 specific binding sites in the brain -- I'm sorry --
- 3 in the central nervous system for nicotine; right?
- 4 A. Well we had access to the scientific literature
- 5 which anyone else interested in the subject had, so
- 6 therefore we had that information of course, yes.
- 7 Q. Well sir, Brown & Williamson also had
- 8 information that was available to it and it alone
- 9 because it wasn't published in the scientific
- 10 literature; isn't that true?
- 11 A. I don't think anything of any consequence, no.
- 12 Q. Well sir, let me show you a document and ask you
- 13 if it was published in the scientific literature.
- 14 (Plaintiffs' Exhibit 4456 marked for
- identification.)
- 16 BY MS. WIVELL:
- 17 Q. Sir, showing you what's been marked as
- 18 Plaintiffs' Exhibit 4456, this is a study entitled
- 19 "RECEPTORS FOR NICOTINE IN THE CENTRAL NERVOUS
- 20 SYSTEM I RADIOLIGAND BINDING STUDIES, REPORT NO.
- 21 RD.1960 RESTRICTED"; correct?
- 22 A. Yeah.
- 23 Q. It's dated March 22nd, 1984.
- 24 A. Correct.
- 25 Q. Was Exhibit 4456 ever published in the

- 1 scientific literature so other scientists could read
- 2 it, sir?
- 3 A. Well I think, and you'd have to bear with me and
- 4 I don't think either of us want to take up all this
- 5 time going through it in detail, but I believe Dr.
- 6 Templeton was really picking up on stuff that had
- 7 already been published in the literature -- I'm
- 8 looking for the references to see where she picked up
- 9 from -- and certainly if you turn to Bates number
- 10 020, there are 20 references there which all refer to
- 11 the external literature, and I think she was just
- 12 beginning to develop some of the in-house expertise
- 13 to follow up on what all these people had been doing.
- 14 Q. Well sir --
- 15 A. So, I'm sorry, this is a long answer to a
- 16 question and I apologize.
- 17 Basically I -- If it probably was not published,
- 18 it probably was not published because it wasn't
- 19 adding anything to what was already here.
- 20 Q. Sir, this particular document reports the study
- 21 of nicotine on rats, doesn't it?
- 22 A. Right.
- 23 Q. And this study, Exhibit 4456, was not published
- 24 in the scientific literature so other scientists
- 25 could read and review it; isn't that true?

- 1 A. Well I don't think it was going to add anything
- 2 to what they already knew.
- 3 MS. WIVELL: Move to strike as
- 4 nonresponsive.
- 5 Q. Sir, my question isn't asking you whether or not
- 6 it's adding anything new.
- 7 My question is simply this: Exhibit 4456 was
- 8 not published in the open scientific literature so
- 9 other scientists could review what Brown & Williamson
- 10 and British-American Tobacco Company knew; isn't that
- 11 true?
- 12 A. Well it wasn't published because it wasn't
- 13 adding anything to what was known.
- 14 Q. Well sir, why did -- Strike that.
- 15 Sir, this study reports in detail the
- 16 development and application of techniques to identify
- 17 and characterize regions within brain tissue where
- 18 nicotine could bind and elicit a pharmacological
- 19 response; right?
- 20 A. Sure, yeah. I mean B.A.T. scientists were
- 21 always keeping up-to-date with the literature that
- 22 was -- work that was going on outside and then
- 23 looking at the methodology in-house to understand it
- 24 and see where it may lead.
- Now this is my recollection, and I have not read

- 1 this now or in preparation for this deposition --
- 2 although I was aware that it was one of the documents
- 3 that you wished to discuss -- but as I say, it's a
- 4 first step at developing the technology in-house to
- 5 understand these procedures, yeah.
- 6 Q. All right. And sir, this study established that
- 7 nicotine bound to at least two sites in the central
- 8 nervous system of the rat; correct?
- 9 A. I'm sure it -- Yeah -- Well I don't know whether
- 10 it did or didn't, but it binds to lots of receptors
- 11 in any organism, you know, from a squid axon to a rat
- 12 to a monkey to me.
- 13 Q. Well sir, if we turn to the page that ends with
- 14 Bates number 999 we see that there is a technical
- 15 abstract; correct?
- 16 A. Yes.
- 17 Q. And the technical abstract says, "A method is
- 18 described to investigate the nature and properties of
- 19 nicotine receptors in the central nervous system...of
- 20 the rat"; right?
- 21 A. Yes.
- 22 Q. And it says, "It has been established that
- 23 nicotine binds to (at least) two" sites -- "two types
- 24 of site"; correct?
- 25 A. Yes.

- 1 Q. And that's what this study established; right?
- 2 A. Right.
- 3 Q. Now sir, you would agree that nicotine is a
- 4 drug, wouldn't you?
- 5 A. In so far as nicotine has pharmacological
- 6 effects and that's how we define a drug, sure, yes.
- 7 Q. All right. And you would agree that the smoking
- 8 act can be a means of nicotine dosing, wouldn't you?
- 9 A. Well that's been hypothesized. I'm not sure.
- 10 Q. Do you know who Graham Read is?
- 11 A. British-American Tobacco Company scientist.
- 12 Q. He actually is head of research and development
- 13 for British-American Tobacco Company, isn't he?
- 14 A. Today, yes.
- 15 Q. And in 1984 he was a scientist who made a
- 16 presentation at a seminar that you attended on
- 17 smoking behavior; isn't that true?
- 18 A. I'm not disputing it but, you know -- I don't
- 19 remember the occasion, but I could very well have
- 20 done so.
- 21 Q. All right, sir. Let me show you what's been
- 22 marked as Exhibit 731. Exhibit 731 begins with the
- 23 Bates number 100535243; correct?
- 24 A. Yes.
- 25 Q. And it is a presentation that Dr. Read gave

- 1 concerning the different levels of nicotine
- 2 interaction; right?
- 3 A. That's the title, yes.
- 4 Q. All right. And this is a presentation he gave
- 5 at a seminar that you attended on behalf of Brown &
- 6 Williamson that was held in Southampton; isn't that
- 7 true?
- 8 A. As I say, so you tell me. I don't dispute it.
- 9 Q. All right.
- 10 MS. WIVELL: I would like to take a break.
- 11 THE REPORTER: Off the record, please.
- 12 (Recess taken from 3:00 to 3:09 p.m.)
- 13 BY MS. WIVELL:
- 14 Q. Sir, directing your attention to Exhibit 731,
- 15 there at the bottom of the first page is a reference
- 16 to the fact that the smoking act can be considered as
- 17 a means of nicotine dosing; correct?
- 18 A. That's what he says, yes.
- 19 Q. All right. Now sir, did Brown & Williamson ever
- 20 tell the people who were smoking its cigarettes in
- 21 any way that they were receiving a drug?
- 22 A. Well I think everyone knows that nicotine's a
- 23 drug.
- 24 Q. Well sir, you haven't done a survey to determine
- 25 whether people know that, do you?

- 1 A. You know, I don't see the need for it, but no,
- 2 we haven't.
- 3 Q. And you can't point me to any research that
- 4 looked at the issue of whether -- whether smokers
- 5 knew that cigarette smoking was a drug.
- 6 A. Well, I'm sorry, that statement, as you
- 7 expressed it, I don't mean to be difficult, but it
- 8 doesn't mean anything.
- 9 Q. Well sir, you're -- you would agree that within
- 10 ten seconds of starting to smoke nicotine's available
- 11 in the brain; right?
- 12 A. Yeah, but the question you asked me before that
- 13 you said I would agree that cigarette smoking is a
- 14 drug, and I -- I mean, cigarette smoking is a habit,
- 15 but cigarette smoking is something someone does so I
- 16 don't see how cigarette smoking can be a drug.
- 17 Q. Well sir, isn't a cigarette a
- 18 drug-administration system?
- 19 A. Not in my view, no.
- 20 Q. Well sir, isn't it true that within ten seconds
- 21 of starting to smoke, a cigarette's nicotine is
- 22 available in the brain?
- 23 A. I'm sure it's in that order, yes.
- 24 Q. All right. And sir, isn't it true that what a
- 25 cigarette really is is a fast, highly

- 1 pharmacologically effective, cheap drug-delivery
- 2 system?
- 3 A. Well certain people have expressed that view,
- 4 but I don't accept that myself.
- 5 Q. Well you know that certain people within the
- 6 B.A.T. group have expressed that view, don't you,
- 7 sir?
- 8 MR. KOMAR: Object to form.
- 9 A. Yes, I do.
- 10 (Interruption by the reporter.)
- 11 A. I'm sorry. There was --
- 12 Are you referring to an employee of
- 13 British-American Tobacco Company?
- 14 Q. Well yes, sir, I'm referring to Colin Greig.
- 15 You're aware that he expressed that view at a
- 16 conference that was held of representatives from
- 17 various B.A.T. group companies that was held in
- 18 Southampton, England; right?
- 19 A. I'm not sure where it was held, but I've seen
- 20 that document. I think we discussed it last time I
- 21 was with you.
- 22 Q. All right. Sir, showing you what's been marked
- 23 as Plaintiffs' Exhibit 516, this is the document that
- 24 you were referring to just a few moments ago, wasn't
- 25 it?

- 1 A. Yes.
- 2 Q. For the record, Exhibit 516 begins with the
- 3 Bates number 100503495; right?
- 4 A. Right.
- 5 Q. And in this document --
- 6 By the way, it was a presentation that Mr. Greig
- 7 gave to a conference, a B.A.T. group conference;
- 8 right?
- 9 A. Correct.
- 10 Q. And in this presentation he talked about the
- 11 drug -- the -- I'm sorry. Strike that.
- 12 In this conference he talked about the cigarette
- 13 as a, quote unquote, drug administration system for
- 14 public use; right?
- 15 A. Yeah, as I understand he was kind of being
- 16 provocative in this first part of the discussion,
- 17 possibly to get the attendees' attention.
- 18 Q. Well sir, it doesn't say he's being provocative,
- 19 does it? It says, "A cigarette as a 'drug'
- 20 administration system for public use has very very
- 21 significant advantages"; doesn't it?
- 22 A. I -- Yeah, that's what the document says, yeah.
- 23 Q. And sir, basically he's talking about, in just a
- 24 little bit different terms, the same thing that Dr.
- 25 Read was talking about in Exhibit 731 when he was

- 1 talking about the smoking act being considered a
- 2 means of nicotine dosing; right?
- 3 A. This is -- Yeah, this is a hypothesis they were
- 4 both discussing.
- 5 Q. Well sir, that was the operative hypothesis
- 6 within the B.A.T. group companies, right, that the
- 7 cigarette is a means of devel -- of delivering a
- 8 pharmacologically active substance, i.e., nicotine,
- 9 to the smoker.
- 10 A. Well it probably varied by the company or varied
- 11 by the person. That's part of cigarette smoking, but
- 12 it's certainly not all of cigarette smoking I'm sure.
- 13 Q. Well sir, would you agree with Dr. Greig when he
- 14 says on the page that ends with Bates number 497,
- 15 "Thus we have an emerging picture of a fast, highly
- 16 pharmacologically effective and cheap 'drug',
- 17 tobacco, which also confers flavor and manual and
- 18 oral satisfaction to the user." Is that what a
- 19 cigarette does, sir?
- 20 A. Not totally to my mind, no.
- 21 Q. Well would you agree that the cigarette is a way
- 22 of -- of delivering a pharmacologically effective
- 23 substance, nicotine, to the smoker?
- 24 A. Well we know that nicotine has pharmacological
- 25 effects. I wouldn't say it's highly

- 1 pharmacologically effective. It certainly has
- 2 pharmacological effects.
- 3 Q. And the cigarette is a good way of delivering
- 4 this pharmacologically active substance to the brain,
- 5 isn't it?
- 6 A. Yeah.
- 7 Q. Now sir, you would agree that the scientific
- 8 community believes cigarette smoking is addictive,
- 9 doesn't it?
- 10 A. Oh, come back again to semantics and
- 11 definition. Defining it my way, no; defining it
- 12 according to whatever it was, the 1988, was it,
- 13 surgeon general's report, I mean certainly people
- 14 will subscribe to that and agree to that, I mean, so
- 15 you'll get two points of view.
- 16 Q. Well sir, you would agree that the point of view
- 17 to which Brown & Williamson subscribes is out of the
- 18 mainstream of scientific thought concerning whether
- 19 cigarette smoking is addictive.
- 20 A. You know, it may be.
- 21 Q. Now sir, if Brown & Williamson believed
- 22 cigarette smoking was addictive, what could they --
- 23 it do to make it nonaddictive?
- 24 A. Well if Brown & Williamson believed that
- 25 cigarette smoking was addictive and they had --

- 1 Well it's very difficult to answer the question
- 2 if you don't have a reason, and as I say, we don't
- 3 believe it's addictive. Now to have people stop
- 4 smoking our cigarettes we could make them so they
- 5 have a nasty taste or the filter would fall off or
- 6 something like that but then all they would do is
- 7 smoke somebody else's cigarettes so that's kind of a
- 8 self-defeating proposition.
- 9 Q. Well sir, you would agree that it is
- 10 technologically feasible to remove nicotine from
- 11 cigarettes, wouldn't -- isn't it?
- 12 A. Yes.
- 13 Q. And that's one thing that Brown & Williamson
- 14 could do if it admitted that cigarette smoking was
- 15 addictive and wanted to make cigarettes nonaddictive;
- 16 right?
- 17 A. Well irrespective of whether or not it admitted
- 18 cigarette smoking is addictive or not, it could do it
- 19 if it was willing to pay a license to Philip Morris,
- 20 who I think has probably got the only commercially
- 21 viable method of denicotinizing tobacco.
- 22 Q. In fact you are aware that folks have sold
- 23 cigarettes made out of other substances, like lettuce
- 24 or herbs; right?
- 25 A. Right.

- 1 Q. People don't buy them, do they?
- 2 A. Not for long.
- 3 Q. No, because they don't have nicotine in them, do
- 4 they?
- 5 A. Well, I mean that could very well be the reason
- 6 but they also have a foul taste and smell so I can't
- 7 see any motive for smoking them.
- 8 Q. Sir, would it be proper to do anything to a
- 9 product to make it more difficult to quit smoking?
- 10 A. Well, you know, I can't even -- I can't even
- 11 begin to think of -- of what one would do, so I'm not
- 12 quite sure what you're asking me.
- 13 Q. Well sir, you would agree it would be improper
- 14 for Brown & Williamson to do anything secretly to its
- 15 cigarettes to try and make it more difficult for a
- 16 smoker to quit smoking; right?
- 17 A. Yes. I --
- 18 Q. You know that most smokers want to quit, don't
- 19 you?
- 20 A. I think the general sort of survey information
- 21 you see would be, and it probably varies by country
- 22 and et cetera, et cetera, et cetera, but, yeah,
- 23 majority, over 50 percent --
- 24 Q. All right. And sir --
- 25 A. -- say they would like to.

- 1 Q. You're aware that smokers continue to smoke --
- 2 MR. McCORMICK: Were you finished with your
- 3 answer?
- 4 THE WITNESS: I think, yeah, the fact that
- 5 they say they would like to.
- 6 Q. Now you're aware that smokers continue to use
- 7 cigarettes even after they have been diagnosed with
- 8 illnesses and have lost organs and have other serious
- 9 reasons to quit; right?
- 10 A. I have seen that stated, yes.
- 11 Q. Now sir, you would agree that the standard
- 12 smoking machine does not tell you what a human smoker
- 13 will get when he smokes a particular brand of
- 14 cigarettes.
- 15 A. Right. I think the Federal Trade Commission
- 16 told us that when it established the method, it said
- 17 it's not intended to.
- 18 Q. Well sir, did Brown & Williamson ever tell the
- 19 people that bought its cigarettes that the
- 20 smoking-machine data that it was providing in its
- 21 ads, for example, did not really tell a person what a
- 22 human smoker would get when they smoked a particular
- 23 brand?
- 24 A. Well the Federal Trade Commission said that
- 25 right up front. Now I -- One can argue whether the

- 1 Federal Trade Commission should have kept on saying
- 2 it, they didn't but --
- 3 Q. Sir, Brown & Williamson never told the smokers
- 4 who were buying its cigarettes that the
- 5 smoking-machine data that it was providing in its ads
- 6 didn't really tell what a person, a human smoker
- 7 would get when they inhaled a particular kind of
- 8 cigarette, did they?
- 9 A. They made no representations of what it
- 10 represented other than this was what came out of the
- 11 cigarette when smoked according to the FTC method.
- 12 Q. All right. Now sir, you would agree that smoker
- 13 compensation exists; right? It happens.
- 14 A. In different ways, at different times, and this
- 15 being, as you know from all your reading, an enormous
- 16 amount of work looking into the subject.
- 17 Q. And Brown & Williamson has known for years that
- 18 smokers compensate in order to maintain a constant
- 19 level of nicotine delivery; right?
- 20 A. Well, no. I mean, that's a hypothesis. There
- 21 would be some evidence that would support that and
- 22 then some evidence would be contradictory to it.
- 23 Q. Well Brown & Williamson had evidence that
- 24 smokers compensated in order to maintain a particular
- 25 level of nicotine; right?

- 1 A. I certainly saw that for a time. When I've been
- 2 looking at more recent literature I'm much less
- 3 convinced than I used to be. I think that as
- 4 cigarettes have changed over the years, so have
- 5 people's smoking habits changed, and I can't remember
- 6 if it was with you or with Mr. Motley [sp], I said
- 7 the jury's still out --
- 8 (Interruption by the reporter.)
- 9 A. -- with you or with Mr. Motley [sp], there's
- 10 still a whole lot of research going on in this area.
- 11 But, I mean, the bottom line is while there is some
- 12 short-term compensation, there doesn't seem to be
- 13 long term, and when people smoke lower-delivery
- 14 cigarettes, their intake, in general, is lower.
- 15 Q. Well sir, you would agree that if a smoker
- 16 smokes a lower-delivery cigarette, in other words,
- 17 one that is advertised as having low tar, and
- 18 compensates unconsciously in order to try and
- 19 increase or get back up to their normal nicotine
- 20 intake, that that person is actually intaking or
- 21 taking in more tar and nicotine than he or she
- 22 normally would; right?
- 23 A. No.
- 24 Q. Well sir, isn't it true that smokers smoke for
- 25 -- to maintain a pharmacological level of nicotine

- 1 in their bodies?
- 2 A. Well a lot of people have thought that. As I
- 3 say, I even thought that myself at one time but I --
- 4 you know, the evidence doesn't really support that
- 5 and it's a much oversimplistic view.
- 6 Q. Well that's a view that was commonly held within
- 7 the B.A.T. group companies, wasn't it, sir?
- 8 A. It was held by many people, as I said, even by
- 9 myself at one time, but I don't subscribe to it
- 10 fully. The more work we do, in some ways the less we
- 11 understand, but it's clear that this simplistic model
- 12 of sort of topping up the fuel tank is not correct.
- 13 Q. Well sir, showing you what's been marked as
- 14 Plaintiffs' Exhibit 608, this is a document entitled
- 15 "HUMAN SMOKING BEHAVIOUR" that was written by a
- 16 British-American Tobacco Company scientist; right?
- 17 A. Well let's zip through to the end. I don't
- 18 know. It doesn't have a -- doesn't tell me. I don't
- 19 know.
- 20 Q. All right. Well you understand that it came
- 21 from British-American Tobacco Company; right?
- 22 A. Well actually there's -- without reading the
- 23 text, there's nothing to identify it, where it has
- 24 come from.
- 25 Q. All right. Well then let me show you what's

- 1 been marked as Plaintiffs' Exhibit 1181 and see if
- 2 that helps you identify Exhibit 608 as a document
- 3 from British-American Tobacco Company.
- 4 Isn't Exhibit 608 actually an attachment to a
- 5 letter that was sent to Brown & Williamson
- 6 International Tobacco by someone at Brown -- at
- 7 British-American Tobacco?
- 8 A. Yeah. Okay. And it says in the letter, "David
- 9 Creighton from Group Research and Development Centre
- 10 was the author of...this paper..."
- 11 Q. All right. David Creighton is a scientist
- 12 within the Group Research and Development Centre at
- 13 British-American Tobacco; right?
- 14 A. At that time he was. I'm not sure what he's
- 15 doing nowadays.
- 16 Q. What was his specialty back then, sir?
- 17 A. Smoking behavior.
- 18 Q. All right. And he wrote this document about
- 19 that very subject, didn't he?
- 20 A. That's what this letter tells us, yes.
- 21 Q. All right. And in fact you've reviewed this
- 22 document in preparation for your deposition; right?
- 23 A. I don't think I did, no.
- 24 Q. All right. Well sir, directing your attention
- 25 to the page -- the first exhibit I gave you that ends

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 with Bates number 312. Dr. Creighton wrote in the
- 2 middle of the paragraph or in the middle of the page,
- 3 "It is generally accepted that a large number of
- 4 habitual smokers are influenced in their smoking
- 5 habit by the amount of nicotine that they draw from a
- 6 cigarette. Over a period of time, during which they
- 7 are learning how to smoke effectively that is so
- 8 that they do not make themselves feel ill, but do
- 9 derive pleasure and satisfaction from smoking they
- 10 probably build up an association in their minds
- 11 between the mouth sensations such as flavour,
- 12 irritation and 'impact' and the amount of smoke that
- 13 gives them the satisfactions of smoking. This is a
- 14 similar mechanism to Pavlov's dogs"; correct?
- 15 A. That's what he says.
- 16 Q. All right. Now sir, what Dr. Creighton is
- 17 talking about here is the mechanism by which a smoker
- 18 associates a certain kind of sensations, including
- 19 flavor, irritation and impact, with a given amount of
- 20 nicotine; right?
- 21 A. No, I don't think that's -- He didn't say that,
- 22 did he? He says that "...they build up an
- 23 association in their minds between the mouth
- 24 sensations such as flavour, irritation and 'impact'
- 25 and the amount of smoke that gives them the

- 1 satisfactions of smoking."
- 2 And here we, you know, again we come to one of
- 3 those words that's so difficult to define because
- 4 what does "satisfactions of smoking" mean other than
- 5 the person that says "I'm satisfied"?
- 6 Q. Well sir, Dr. Creighton goes on to note,
- 7 "Nicotine is the most pharmacologically active
- 8 constituent in cigarette smoke and is most probably
- 9 the usual factor responsible for the maintenance of
- 10 the smoking habit"; correct?
- 11 A. That's what he says, yes.
- 12 Q. Now sir, would you agree that nicotine is the
- 13 most pharmacologically active constituent in tobacco
- 14 smoke?
- 15 A. Certainly in a total-mass basis, yes.
- 16 Q. And would you agree with what Dr. Creighton
- 17 wrote when he said it is most probable that nicotine
- 18 is the most usual factor responsible for the
- 19 maintenance of the smoking habit?
- 20 A. Yes.
- 21 Q. Would you agree that the smoker does build up a
- 22 certain association with the level of nicotine intake
- 23 when he or she puffs on a cigarette?
- 24 A. Possibly, but I'm not a hundred percent
- 25 convinced. But possibly, yes.

- 1 Q. Well sir, would you agree that any health
- 2 advantages that a low-tar cigarette might offer a
- 3 smoker would be affected if that smoker compensates
- 4 in order to make up for lower-nicotine delivery?
- 5 A. Well you're asking me to make a lot of
- 6 assumptions there, but if you are making the
- 7 assumption that health risk is related to amount of
- 8 tar ingested, and if you are saying if a person
- 9 smokes a lower machine tar number but gets more tar
- 10 is there any change in health risk from the previous
- 11 tar number, you would say no. That's, you know,
- 12 assuming all your assumptions hold.
- 13 Q. Well sir, isn't it a fact that British-American
- 14 Tobacco Company scientists concluded that the
- 15 advantages of low-tar or low-retention cigarettes
- 16 would be affected if smokers compensate in response
- 17 to changes in cigarette design?
- 18 A. Well as I say, if all those assumptions hold,
- 19 then yes.
- 20 Q. Sir, showing you what's previously been marked
- 21 as Plaintiffs' Exhibit 953, this is a study entitled
- 22 "COMPENSATION: A REVIEW, THE RELATIONSHIP BETWEEN
- 23 COMPENSATION AND CHANGES IN CIGARETTE DESIGN, REPORT
- 24 NO. RD.1725" that was issued in 1980 by Group
- 25 Research and Development at Southampton; right?

- 1 A. Right.
- 2 MR. McCORMICK: Excuse me. Let me
- 3 interject, before we leave this other exhibit. I'm
- 4 going to -- I'd like to interject an objection to the
- 5 marking of Plaintiffs' Exhibit 608. I realize it
- 6 wasn't marked in this deposition, but you've been
- 7 interrogating this witness about a document marked as
- 8 Plaintiffs' Exhibit 1181, which appears to contain
- 9 the earlier Exhibit 608, and if Exhibit 1181 is in
- 10 fact a authentic document, demonstrates that Exhibit
- 11 608 is not, and indeed is an incomplete document.
- 12 I don't know what purpose you had in attempting
- 13 to use just that portion of it, but we'd object to
- 14 its having been marked, apparently, as an incomplete
- 15 document.
- 16 BY MS. WIVELL:
- 17 Q. Sir, directing your attention -- I'm sorry.
- Directing your attention back to Exhibit 953,
- 19 this was a document, a report that was issued by
- 20 Group Research and Development and then sent to Brown
- 21 & Williamson; right?
- 22 A. Right.
- 23 Q. And the authors begin their summary of the
- 24 report by saying, "The advantages of low-tar or
- 25 low-retention cigarettes will be affected if smokers

- 1 compensate in response to the changes in cigarette
- 2 design"; right?
- 3 A. That's what it says, yes.
- 4 Q. Did Brown & Williamson ever tell the people to
- 5 whom it advertised low-tar cigarettes that, oh, by
- 6 the way, if you compensate you're going to lose any
- 7 health advantage that these cigarettes might give
- 8 you?
- 9 A. Well, we have never represented that cigarettes
- 10 with lower Federal Trade Commission numbers are
- 11 supposed to conver -- confer any health advantages.
- 12 Q. Well, sir, did Brown & Williamson ever tell the
- 13 people to whom it marketed low-tar, or even low-gas
- 14 cigarettes, that if they compensated, the advantages
- 15 of these cigarettes would be affected?
- MR. McCORMICK: Objection, that's asked and
- 17 answered.
- 18 A. I believe I answered you, Ms. Wivell.
- 19 Q. They didn't tell them, did they, sir?
- 20 A. I said we never claimed any health advantages.
- 21 Q. My question didn't even mention "health
- 22 advantages, " sir. Let me repeat it so you can hear
- 23 it again.
- "...did Brown & Williamson ever tell the people
- 25 to whom it marketed low-tar, or even low-gas

- 1 cigarettes, that if they compensated, the advantages
- 2 of these cigarettes would be affected?"
- 3 MR. McCORMICK: Do you want to clarify
- 4 which advantages you're referring to, Ms. Wivell, if
- 5 they weren't health advantages?
- 6 MS. WIVELL: My question is what my
- 7 question is, sir.
- 8 A. Okay. Let me take it in two parts. The general
- 9 health advanta -- did you say advan -- Sorry, getting
- 10 confused.
- 11 Whatever general advantages you are referring
- 12 to, I mean, we didn't make any representations of
- 13 cigarettes overall. The only instance I can think of
- 14 was in some FACT advertising where they're talking
- 15 about the filter lowering the levels of certain
- 16 irritating compounds. No, we did not say in that
- 17 advertisement, if you smoke it -- puff it harder
- 18 you'll get just as much irritating compounds as you
- 19 -- without our special filter, so in that particular
- 20 instance we didn't, no.
- 21 Q. All right. But this particular document,
- 22 Exhibit 953, talks about the advantages in the
- 23 beginning of that sentence; right?
- 24 A. Well, I mean, that is what that sentence
- 25 states. At the moment, I don't know what that

- 1 sentence means.
- 2 Q. Well sir, isn't it true that Brown & Williamson
- 3 marketed low-tar, low-retention cigarettes with the
- 4 implied health warning, or the implied suggestion
- 5 that those cigarettes were healthier for smokers?
- 6 A. We marketed lower-tar cigarettes in response to
- 7 public demand which was basically driven by health
- 8 authorities.
- 9 Q. So are you denying that Brown & Williamson's
- 10 marketing implied or suggested health effects for
- 11 low-tar cigarettes?
- 12 A. What I'm saying is that we never represented
- 13 that there would be any health advantages to a person
- 14 using a lower-tar cigarette compared to a normal-tar
- 15 cigarette.
- 16 Q. Sir, isn't it true that Brown & Williamson
- 17 featured prominently in its ads lower-tar claims for
- 18 its cigarettes in order to imply or suggest health
- 19 effects for those cigarettes?
- 20 A. Boy, we could argue about this forever but, I
- 21 mean, the basic fact is we did not make any health
- 22 representation. Health authorities, particularly
- 23 prior to the late '70s when they decided no cigarette
- 24 was a good cigarette, were encouraging tobacco
- 25 companies to market lower-tar cigarettes, and that's

- 1 exactly what all the tobacco companies were doing.
- 2 Q. Well sir, if there weren't any suggested or
- 3 implied health claims or health effects, why did
- 4 Brown & Williamson put its tar advertising so
- 5 prominently, its tar figures so prominently in their
- 6 ads?
- 7 A. Because consumers, hearing what health
- 8 authorities had said, were -- many of them were
- 9 electing to buy lower-tar cigarettes.
- 10 Q. And sir, wasn't it Brown & Williamson's purpose
- 11 to try and prevent smokers who had an intention to
- 12 quit smoking to instead detour to these low-delivery
- 13 cigarettes?
- 14 A. No. I mean, a person is free to quit smoking
- 15 whenever they choose to.
- 16 (Discussion off the stenographic record.)
- 17 BY MS. WIVELL:
- 18 Q. Sir, showing you what's previously been marked
- 19 as Plaintiffs' Exhibit 949, this is a document that
- 20 you received from Dr. E. F. Litzinger entitled
- 21 "SOCIAL SMOKING STUDIES"; right?
- 22 A. I was copied on it, yes.
- 23 Q. All right. Could you please read aloud for the
- 24 ladies and gentlemen of the jury the first paragraph
- 25 of that document.

- 1 A. "We search for answers to the questions 'Why do
- 2 people smoke?' and 'Why do people stop smoking?' to
- 3 provide us with direction in developing new
- 4 products. Perhaps answers to another question 'How
- 5 do people stop smoking?' could lend insight into the
- 6 creation of new products. Having answers to this
- 7 latter question we might then design products to
- 8 'intercept' people who are trying to give up
- 9 smoking."
- 10 Q. Let me repeat my question, sir.
- 11 Isn't it true that Brown & Williamson's attempt
- 12 to produce low-tar cigarettes was an attempt to try
- 13 and get people to quit smo -- to detour away from
- 14 quitting smoking?
- 15 A. No, Litzinger here is looking for ways of
- 16 developing some new products that might interest
- 17 people. And we go on to the next paragraph, he's
- 18 talking about something that actually could very well
- 19 help someone to quit, because it would give them a
- 20 little dial on their cigarettes --
- 21 (Interruption by the reporter.)
- 22 A. -- dial, so they could -- so they could keep on
- 23 dialing down the amount and, in theory, they could
- 24 wean themselves off.
- 25 Q. Sir, isn't it true that Brown & Williamson

- 1 looked at low-tar, low-delivery cigarettes as a way
- 2 to stem the continuing decline in people who were
- 3 quitting smoking?
- 4 A. Well I don't know. You may have a document that
- 5 says that, but I -- you know, I'll make my point. If
- 6 people want to smoke, they'll smoke. If they don't
- 7 want to smoke, they don't smoke.
- 8 Q. Sir, directing your attention to point number 3
- 9 on the second page of what has been marked as Exhibit
- 10 948, would you please read the first sentence of
- 11 point number 3 to the ladies and gentlemen of the
- 12 jury.
- MR. McCORMICK: Let me see it. Just a
- 14 minute.
- 15 Are you planning to identify this for the
- 16 record, Ms. Wivell, as to what this is or where it
- 17 came from?
- 18 MS. WIVELL: After he reads the sentence to
- 19 the jury, that would be fine.
- 20 A. It was the -- On page 2, the one that was number
- 21 3.
- 22 Q. Point 3, yes, sir.
- 23 A. Point 3. "To stem the continued decline in
- 24 smoking incidence, the industry must rapidly move to
- 25 a point where it can address cigarettes in a totally

- 1 positive light. Low gas will help in terms of
- 2 reducing personal concerns of active and passive
- 3 smokers, yet the consumption of low gas brands will
- 4 emerge as a negative self-statement with continued
- 5 personal consumption."
- 6 Q. Now sir --
- 7 A. Sorry, Ms. Wivell, do you want me to read the
- 8 whole thing?
- 9 Q. No, that's fine.
- 10 A. Yeah.
- 11 Q. That document is a document that concerns the
- 12 hi-fi market; isn't that true?
- 13 A. Well, I don't know, because it's a very poor
- 14 copy and we can't read the preceding two paragraphs
- 15 and --
- 16 Q. All right. But we can read the first paragraph
- 17 of the document, can't we, sir?
- 18 A. Well it's about something called a Purite
- 19 filter, and it says that it is a situation analysis.
- 20 Do you want me to read that?
- 21 Q. Well sir, it refers to the hi-fi market, doesn't
- 22 it?
- 23 A. It says "The move to hi-fi cigarettes" -- I
- 24 think it's a typo, it says "in continuing," but I
- 25 guess it means is continuing.

- 1 Q. Now sir, "hi-fi cigarettes" are high-filtration
- 2 cigarettes; right?
- 3 A. That was a term used by the marketing people,
- 4 yeah.
- 5 Q. Now sir, turning back to the subject of
- 6 nicotine, you would agree that approximately 90
- 7 percent of inhaled nicotine is absorbed by the body,
- 8 wouldn't you?
- 9 A. Yeah, once it's inhaled most of it seems to be
- 10 absorbed.
- 11 Q. And sir, you would agree that smokers can
- 12 control their nicotine uptake; correct?
- 13 A. Well, in the sense that they can either take
- 14 more puffs or less puffs, put the cigarette out, take
- 15 bigger puffs. I don't know that they're consciously
- 16 controlling their nicotine uptake, but their nicotine
- 17 uptake will change according to how many puffs they
- 18 take on the cigarette.
- 19 Q. And sir, you would agree that for most of the
- 20 years that you were at Brown & Williamson it was
- 21 Brown & Williamson's working hypothesis that the
- 22 important factor in a cigarette was not the amount of
- 23 nicotine in the smoke, but rather the amount of free
- 24 nicotine in the smoke which determined the degree of
- 25 smoke impact; right?

- 1 A. I think we have said too many things all at
- 2 once. I'll agree to part of it, which is that this,
- 3 quote, free nicotine -- and I'll have to explain a
- 4 bit later on on this, is a misnomer -- but there was
- 5 a working hypothesis that impact, the immediate
- 6 sensation, is somehow related to something called
- 7 either free nicotine or extractable nicotine or
- 8 smoking pH, but yes, something associated along those
- 9 lines.
- 10 Q. Well sir, when we first chatted back earlier in
- 11 this year in June I asked you about a document that
- 12 said: "The important factor, though, is not the
- 13 amount of nicotine in the smoke, per se, but rather
- 14 it is the amount of free nicotine in the smoke which
- 15 determines the degree of smoker impact," and you
- 16 answered "yes"; right?
- 17 And then I asked you: "And that was a working
- 18 hypothesis you had during the entire time you were at
- 19 Brown & Williamson; isn't that true, sir?" and you
- 20 answered yes. I'm sorry, you answered, "That's
- 21 true."
- 22 Isn't that correct?
- 23 A. Let's have a look.
- 24 This first question you asked me goes on to say
- 25 -- So I'm -- The first "yes" agrees that you were

- 1 quoting from whatever we were looking at.
- 2 Q. And the second "yes" agrees that that statement
- 3 that I quoted out of the document was a working
- 4 hypothesis the entire time you were at Brown &
- 5 Williamson; isn't that true?
- 6 A. Which determines the degree of smoke impact, the
- 7 immediate sensation, yeah.
- 8 Q. Now sir, you would agree that the pH of
- 9 cigarette smoke is critical in determining the amount
- 10 of nicotine which is absorbed by the smoker's body;
- 11 right?
- 12 A. No, not at all.
- 13 Q. Well sir, isn't it true that the pH of smoke is
- 14 important and becomes critical if sufficient amounts
- 15 of nicotine are to be absorbed by the lungs?
- 16 A. No.
- 17 Q. Did you attend a conference, a scientific
- 18 research group conference in Montreal in August of
- 19 1986?
- 20 A. I don't think so but, I mean, if I did, I did,
- 21 but I don't think I did.
- 22 (Plaintiffs' Exhibit 4457 marked for
- 23 identification.)
- 24 BY MS. WIVELL:
- 25 Q. Sir, showing you what's been marked as

- 1 Plaintiffs' Exhibit 4457, this is a "Note on
- 2 recommendations for future research interests given
- 3 at the 2nd meeting of the Scientific Research Group -
- 4 Montreal, August 6-8, 1986"; right?
- 5 A. Okay. And let me correct something I -- I said
- 6 earlier. Because it says "Montreal," and that wasn't
- 7 ringing any bells with me, I think I attended this
- 8 meeting and the reason I said "no" is because it was
- 9 some -- someplace outside of Montreal. I mean, it
- 10 was in Canada, but I can't remember what it was
- 11 called so --
- 12 Q. You attended the meeting that's referred to in
- 13 Exhibit 4457; right?
- 14 A. I attended a meeting up in Canada sometime
- 15 around that time so it may very well have been this
- 16 one.
- 17 Q. Now sir, you were Brown & Williamson's
- 18 representative on the Scientific Research Group,
- 19 weren't you?
- 20 A. You know, at times I was and at times I wasn't
- 21 and that's -- I'm struggling. I think it was likely
- 22 I attended this one, but I'm not -- still not a
- 23 hundred percent sure.
- 24 Q. Now sir, there is a portion of this document
- 25 that addresses the pharmacokinetics of nicotine;

- 1 right?
- 2 A. Yes.
- 3 Q. And it talks there about absorption --
- 4 A. Right.
- 5 Q. -- at the second page of Exhibit --
- 6 A. Right.
- 7 Q. -- 4457; right?
- 8 A. Yeah, yeah.
- 9 Q. You have to let me finish, sir.
- 10 Correct?
- 11 A. Sorry. "Correct" that I have to let you
- 12 finish?
- 13 Q. No, correct that there's a portion of the
- 14 document that refers to pharmacokinetics of
- 15 nicotine.
- 16 A. Yes.
- 17 Q. And there is a brief summary of nicotine
- 18 pharmacokinetics there; right?
- 19 A. Yes.
- 20 Q. By the way, what do "pharmacokinetics" mean?
- 21 A. The rate at which nicotine would be absorbed and
- 22 subsequently metabolized.
- 23 Q. All right. And sir, under "Absorption" it says,
- 24 "The pH of...smoke is critical in determining the
- 25 amount of nicotine absorbed", doesn't it?

- 1 A. Well that's what it says but it's wrong, and I'm
- 2 really surprised.
- 3 Q. And it goes on to say, "The inhalation of the
- 4 smoke then becomes critical if "sufficient "amounts
- 5 of nicotine are to be absorbed by the lungs";
- 6 correct?
- 7 A. Yes.
- 8 Q. And it talks about absorption of nicotine via
- 9 the lungs being almost as efficient as intravenous
- 10 administration of nicotine; right?
- 11 A. Yes.
- 12 Q. Now you would agree that nicotine crosses the
- 13 blood -- I'm sorry. Strike that.
- 14 You would agree that nicotine delivered by a
- 15 cigarette puff crosses the blood-brain barrier;
- 16 right?
- 17 A. A substantial portion of it does, yes.
- 18 Q. Now this document goes on to talk about how fast
- 19 that nicotine from a puff of cigarettes travels from
- 20 the lungs via the bloodstream to the brain; right?
- 21 A. Guide me. I'm sure it does.
- 22 Q. If you turn to the next page under
- 23 "Distribution."
- 24 A. Yeah, yeah.
- 25 Q. You see that there, don't you, sir?

- 1 A. Sorry. What was it we were saying?
- 2 Q. Sir, there in the third page --
- 3 A. Oh, yeah. About eight seconds, and the
- 4 extremities about 20 seconds. Okay. Yep.
- 5 Q. All right. And just so we're clear here, this
- 6 document relates that nicotine reaches the brain in
- 7 about eight seconds; right?
- 8 A. Right.
- 9 Q. Now sir, you would agree that nicotine does get
- 10 from the lungs into the brain in about eight seconds
- 11 after a cigarette smoker takes a puff of smoke.
- 12 A. That's apparently what all the evidence is
- 13 showing, yes.
- 14 Q. Now sir, you would agree that it has been known
- 15 within Brown & Williamson for years that the kick of
- 16 a cigarette was due to the concentration of nicotine
- 17 in the bloodstream.
- 18 A. Oh, I'm not quite sure what we mean by the
- 19 "kick" of a cigarette.
- 20 Q. Well sir, isn't it true that the sensation that
- 21 a smoker gets as a result of taking a puff of
- 22 cigarette smoke is often referred to within Brown &
- 23 Williamson as the "kick" of a cigarette?
- 24 A. I'm trying to think. There's the immediate
- 25 sensation on inhalation which is generally referred

- 1 to as impact. Is that what you're meaning by
- 2 "kick"?
- 3 Q. Well, sir, let's take a look at what some of the
- 4 Brown & Williamson scientists or -- I'm sorry --
- 5 Let's take a look at what some of the
- 6 British-American Tobacco scientists were referring
- 7 to.
- 8 Let me show you what's been marked as
- 9 Plaintiffs' Exhibit 332. This is a document that
- 10 begins with the Bates number 100059066; right?
- 11 A. Right.
- 12 Q. And this is a document dated 1964.
- 13 A. Yes.
- 14 Q. And it says on the second page of the document,
- 15 "There seems no doubt that the kick," in quotes, "of
- 16 a cigarette is due to the concentration of nicotine
- 17 in the blood-stream..." Have I read correctly so
- 18 far?
- 19 A. Yeah, you're reading what -- I mean, you're
- 20 reading correctly what the author writes, and the
- 21 "kick" is in quotes, and this is an English
- 22 document, and even English by birth I'm still not a
- 23 hundred percent sure what he's meaning.
- 24 Q. All right. Well sir, isn't it true that it's
- 25 been known throughout the B-A-T group that the kick

- 1 or the impact of a cigarette is due to the
- 2 concentration of nicotine in the bloodstream?
- 3 MR. KOMAR: Object to form.
- 4 MR. McCORMICK: Can I hear that again,
- 5 please? I'm sorry.
- 6 (Record read by the reporter.)
- 7 A. We don't think the impact of a cigarette has
- 8 anything to do with the nicotine concentration in the
- 9 bloodstream.
- 10 Q. Well this document goes on to say, "There seems
- 11 no doubt that the 'kick' of a cigarette is due to the
- 12 concentration of nicotine in the blood-stream which
- 13 it achieves and this is a product of the quantity of
- 14 nicotine in the smoke and the speed of transfer of
- 15 that nicotine from the smoke to the blood-stream";
- 16 correct?
- 17 A. Well this is something that was written in
- 18 1964. I kind of half see what he's getting at but
- 19 I'm not sure that I agree with what he's saying. And
- 20 I think it's because we don't know what he's meaning
- 21 by "kick" because it's not, at least in my mind, a
- 22 common term --
- 23 Q. Well sir --
- 24 A. -- and --
- 25 Q. I'm sorry.

- 1 A. See, there's this thing that you see from time
- 2 to time in here, speed of transfer --
- 3 (Interruption by the reporter.)
- 4 A. The statement that we see from time to time in a
- 5 number of documents about the speed of transfer of
- 6 nicotine from smoke to the bloodstream -- and you'll
- 7 have to bear in mind that I am not a pharmacologist
- 8 or a physiologist -- but as I understand it, once
- 9 smoke is inhaled, all that is inhaled, irrespective
- 10 of pH, most all that's inhaled is absorbed in the
- 11 lungs and that it's transferred at whatever rate it's
- 12 going to be transferred to the bloodstream, which is
- 13 controlled more by the body fluids in that part of
- 14 anything rather than the properties of the smoke, per
- 15 se.
- 16 Q. Well sir, keeping in mind that -- I'm sorry.
- 17 Strike that.
- 18 You said you're not a pharmacologist; right?
- 19 A. Correct.
- 20 Q. And you know that Brown & Williamson has
- 21 documents which address the speed at which nicotine
- 22 is absorbed by the body; right?
- 23 A. Yeah, I -- I said that there are a number of
- 24 documents which refer to the speed of uptake, but I
- 25 -- I don't think there's any, you know, good

- 1 evidence to show there's any difference in speed of
- 2 uptake once nicotine is inhaled.
- 3 Q. Well that's not your area of professional
- 4 competence, is it, sir?
- 5 A. No, but as I say, I can read just as well as you
- 6 and I don't recollect seeing anything in the
- 7 scientific literature, and I may be wrong, but I
- 8 don't recollect seeing anything that really does
- 9 influence the speed of uptake once it's inhaled.
- 10 Q. Have you read the document "The Fate of Nicotine
- 11 in the Body" which British-American Tobacco Company
- 12 provided to Brown & Williamson back in the '60s?
- 13 A. Is this a Battelle report?
- 14 Q. Yes, sir.
- 15 A. If you let me see it, then I can probably tell
- 16 you how recently I read it.
- 17 Q. Well can you remember ever reading a document
- 18 entitled "The Fate of Nicotine in the Body"?
- 19 A. Well there may be several documents with that
- 20 title, that's why I'm not sure that I've read that
- 21 particular one.
- 22 Q. Well sir, let me show you this document that
- 23 refers to "The Fate of Nicotine in the Body," it's
- 24 Exhibit 717. For the record, the Bates number is
- 25 536480910; right?

- 1 A. Right.
- 2 Q. And this document starts out by referring to the
- 3 document entitled "The Fate of Nicotine in the Body";
- 4 right?
- 5 A. Right.
- 6 Q. And it goes on to say, in the very simplest and
- 7 incomplete language, this article gives the
- 8 background from which the following can be deduced.
- 9 Have I read correctly so far?
- 10 A. Yes.
- 11 Q. And it says, "Nicotine is absorbed by the body
- 12 in varying amounts depending on smoking habits and
- 13 the body chemistry of the individual. Other factors
- 14 are the more rapid absorption of the free alkaloid
- 15 than the salts"; correct?
- 16 A. Yes.
- 17 Q. It goes on to say, "Its movement is through the
- 18 cell walls of the respiratory passage or the stomach
- 19 into the blood stream"; right?
- 20 A. Right.
- 21 Q. Now you understand that "free alkaloid" is a
- 22 reference to free or unbound nicotine there; right?
- 23 A. Yes.
- 24 Q. All right. And sir, isn't it true that Brown &
- 25 Williamson and British-American Tobacco had

- 1 scientific evidence that unbound nicotine affected
- 2 the body faster and was absorbed faster than bound
- 3 nicotine?
- 4 A. Well that's -- let's sort of take -- break it
- 5 down in several bits.
- 6 Nicotine is a base, and when people refer to
- 7 "free nicotine" they're referring to the
- 8 unprotonated form, and certainly if I put a drop of
- 9 free nicotine on my skin it would be absorbed much
- 10 more rapidly than if I put a drop of nicotine citrate
- 11 on my skin, but when we get down to the very small
- 12 concentrations of nicotine in the aerosol particles
- 13 that somebody inhales and subsequently gets deposited
- 14 in the lung, I think in general this little tiny
- 15 particle is spread over this area the size of a
- 16 tennis court, it doesn't -- doesn't make any -- any
- 17 difference, they get -- they get absorbed real
- 18 rapidly.
- 19 Q. Well in expressing that opinion, sir, did you
- 20 have in mind the results of a study entitled "Further
- 21 Work on Extractable Nicotine" that was done at the
- 22 Group Research and Development Centre of
- 23 British-American Tobacco Company and shared with
- 24 Brown & Williamson?
- 25 A. There was a scientist called Backhurst who did a

- 1 lot of work in this area. He developed some
- 2 hypothesis related to speed of absorption, I think
- 3 then subsequently he said he needed to do some more
- 4 work, and I think he did some more work and
- 5 eventually decided it wasn't the speed of
- 6 absorption. That's my overall recollection of the
- 7 area.
- 8 Q. Well sir, can you direct me to a particular
- 9 document that basically retracts the work that Dr.
- 10 Backhurst had done and provided to Brown & Williamson
- 11 that is entitled "Further Work on Extractable
- 12 Nicotine"?
- 13 A. Not here in this room. I believe one exists.
- 14 Q. But you have seen the research work that Dr.
- 15 Backhurst put together that has been marked as
- 16 Plaintiffs' Exhibit 966; right?
- 17 A. Yes.
- 18 Q. All right. And it -- That work concludes that
- 19 the form of nicotine affects the rate at which it is
- 20 absorbed in the body; right?
- 21 A. Well I'm not sure it concludes. He says it --
- 22 it's his working hypothesis, he says, "Further
- 23 experimental work will be undertaken in an effort to
- 24 confirm the validity..."
- 25 Q. And it -- he also has demonstrated that it -- or

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 concluded that it appears that "increased smoker
- 2 response is associated with nicotine reaching the
- 3 brain more quickly"; isn't that true?
- 4 A. Sorry. Where are we?
- 5 Q. The middle of the "SUMMARY AND CONCLUSIONS"
- 6 page, sir.
- 7 A. He says, "It would appear...the increased smoker
- 8 response is associated with nicotine reaching the
- 9 brain more quickly," but he -- I mean before that he
- 10 says "The reasons for the relationship between smoker
- 11 response and 'extractable' nicotine content of the
- 12 smoke remain obscure. Several possible explanations
- 13 have been considered, " and so on and so on. So, I
- 14 mean, I wouldn't say he's concluded. I would say
- 15 he's struggling to find some answers.
- 16 Q. And sir, he refers to a previously -- a previous
- 17 report in which it was shown that the reaction of a
- 18 smoker to the strength of a cigarette was correlated
- 19 with the weight of extractable nicotine in the smoke
- 20 rather than the total nicotine in the smoke; correct?
- 21 A. Yeah, and if I -- I stand to be corrected by
- 22 you, but I believe here when they're refer to smoke
- 23 -- to "strength" of the smoke they're referring to
- 24 the impact sensation.
- 25 Q. Well sir, the authors of this document, Exhibit

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 966, concluded that "Rapid absorption of vapour phase
- 2 nicotine could explain a rapid transfer of nicotine
- 3 to the brain"; right?
- 4 A. Well rapid absorption of vapor phase nicotine
- 5 could explain a rapid transfer of nicotine into the
- 6 brain, but I -- at the pH of cigarette smoke there
- 7 isn't any vapor-phase nicotine.
- 8 Q. Well sir, isn't it true that Brown & Williamson
- 9 and the British-American Tobacco Company operated
- 10 under the assumption for years that increased smoker
- 11 response depended on a higher amount of extractable
- 12 nicotine reaching the lungs and therefore reaching
- 13 the brain more quickly?
- 14 A. Well, if some people did, they were wrong. I
- 15 don't think that was the majority view.
- 16 Certainly this extractable nicotine correlated
- 17 very well with the impact sensation, that's the catch
- 18 in the back of the throat when they inhale, and if
- 19 you remember we talked quite a lot last time I was
- 20 with you about how this extractable nicotine is -- is
- 21 a, if you like, a test-tube method which is somewhat
- 22 removed from the actual smoking experience and
- 23 sensation.
- 24 Q. Now sir, isn't it true that it was a working
- 25 hypothesis at Brown & Williamson for almost the

- 1 entire time you were there that if the pH of smoke
- 2 increased and became more alkaline, the impact
- 3 sensation would also increase?
- 4 A. Yes. I think that's more than a working
- 5 hypothesis, if I heard you correctly, as smoke pH
- 6 increased, the impact sensation increased.
- 7 Q. And sir, isn't it true that Brown & Williamson
- 8 and British-American Tobacco Company continued to
- 9 look at and work at the issue -- work on the issue of
- 10 the relationship between smoke pH and extractable
- 11 nicotine?
- 12 A. Yes.
- 13 Q. And you would agree that Brown & Williamson
- 14 worked on and looked at the issue of whether smoke pH
- 15 and extractable nicotine was important to smoker
- 16 response to cigarettes; right?
- 17 A. Yeah, in terms of this impact sensation, which
- 18 is something you can measure with smoke panels.
- 19 Q. Well sir, it's more than impact sensation, it's
- 20 smoker response, isn't it?
- 21 A. Well that's why I was careful to say "impact
- 22 sensation" because "impact sensation" I don't think
- 23 we have any disagreements on.
- 24 Whether higher smoke pH gave greater smoker
- 25 satisfaction, however we define it, I don't -- I

- 1 mean, that -- that doesn't bear out, doesn't hold
- 2 water, doesn't stand up.
- 3 Q. Well sir, let me show you what's been marked
- 4 previously as Plaintiffs' Exhibit 962. This is a
- 5 scientific report that was issued by Dr. Sanford;
- 6 correct?
- 7 A. Yeah.
- 8 Q. And it looks at whether -- I'm sorry.
- 9 This particular document studied whether smoke
- 10 pH influenced smoker response; right?
- 11 A. Let's see. The title is the "...AQUEOUS EXTRACT
- 12 pH AND EXTRACTABLE NICOTINE STUDIES OF MAJOR
- 13 CIGARETTE BRANDS FROM BROWN & WILLIAMSON..." Guide
- 14 me where they're talking about response. Okay, the
- 15 extract, here.
- 16 Q. Well the first sentence, sir.
- 17 (Interruption by the reporter.)
- 18 (Discussion off the stenographic record.)
- 19 A. The abstract states that: "The results
- 20 presented here are products of an effort to
- 21 understand the origins of smoke pH and the extent of
- 22 its influence on smoker response."
- 23 Q. Now this work was done because data seemed to
- 24 indicate a demand in the U.S. domestic market for
- 25 brands which had a higher extractable nicotine

- 1 delivery; right?
- 2 MR. McCORMICK: Are you asking him if
- 3 that's what the document says, Ms. Wivell?
- 4 A. The document says in the second paragraph of the
- 5 summary, "The data seem to indicate a demand in the
- 6 domestic market for those brands in the higher
- 7 extractable nicotine range."
- 8 Q. And sir, it's true, isn't it, that the work that
- 9 Brown & Williamson had done looking at other
- 10 cigarettes and other cigarette sales, indicated to
- 11 Brown & Williamson that those brands which seemed to
- 12 be more successful were brands which had a higher
- 13 extractable nicotine range; correct?
- 14 MR. McCORMICK: Is that -- Again, are you
- 15 asking him if that's what the document says?
- If you won't clarify that, I'll object to the
- 17 question on the grounds that there's no foundation
- 18 for it. And if you are asking him that, if you could
- 19 point to the place where it says that, it would
- 20 facilitate matters.
- 21 Q. Do you have the question in mind, sir?
- 22 A. Well, I think so. This work was done by a
- 23 couple of chemists in an analytical group in 1969,
- 24 and they looked at a few cigarettes and, for example,
- 25 I'm just going to quote at random from page 4.

- 1 "Those brands in the pH range 6.0 to 6.3
- 2 (except for the Lorillard brands), B&W and Philip
- 3 Morris, have an average extractable nicotine of 0.38
- 4 milligrams per cigarette and have shown the greatest
- 5 sales fluctuation activity and, with the exception of
- 6 VICEROY, with a general trend toward increasing
- 7 sales."
- 8 So if you take out "Lorillard" and take out
- 9 "Viceroy," it doesn't seem to leave a whole lot. I
- 10 mean certainly this was a hypothesis these guys were
- 11 working on, and I don't dispute that we worked on the
- 12 hypothesis that increasing the extractable nicotine
- 13 might make our cigarettes more preferred. In fact it
- 14 didn't, but that was certainly a hypothesis we worked
- 15 on.
- 16 Q. Sir, it was a hypothesis that you worked on up
- 17 to and including the time you retired from Brown &
- 18 Williamson; isn't that true?
- 19 A. If not when I retired, probably close, sure.
- 20 Q. And it was a hypothesis that was a working
- 21 hypothesis at Brown & Williamson up till the day the
- 22 FDA asserted authority over cigarettes as drugs;
- 23 isn't that true?
- 24 A. You know, I can't speak for that because I'd
- 25 been gone for I guess a year and a half and the last

- 1 couple of years I was at Brown & Williamson I wasn't
- 2 in the mainstream of product development either but,
- 3 you know, for a considerable period of time it was
- 4 thought that it would be one of the factors involved
- 5 in preference. By no means total, but a factor.
- 6 Q. And sir, didn't we chat about the FDA's affect
- 7 on the change of thinking at Brown & Williamson in
- 8 our last deposition?
- 9 A. Well I'm not sure that the FDA changed Brown &
- 10 Williamson's thinking, it may have caused them to
- 11 review some old documents and find out the facts that
- 12 were incorrect in them.
- 13 Q. Sir, the FDA proposed regulating cigarettes as
- 14 drugs in approximately late 1994; right?
- 15 A. Yeah.
- 16 Q. And up to the time that the FDA proposed to
- 17 regulate cigarettes as drugs, Brown & Williamson
- 18 operated under the assumption that increased nicotine
- 19 -- I'm sorry -- that increased pH of smoke would, in
- 20 turn, deliver more unbound or unprotonated nicotine
- 21 to the smoker; right?
- 22 A. No, you know, that wasn't -- When doing product
- 23 development you're trying to find a cigarette that
- 24 people like the taste of. There were some people
- 25 working in product development that thought this was

- 1 an important part of it, there were others that --
- 2 working in product development never, ever measured
- 3 smoke pH or gave it a second thought. So no, I don't
- 4 think you can characterize Brown & Williamson's
- 5 product development as being that at all.
- 6 Q. Who's Tilford Riehl?
- 7 A. He's currently the vice-president of R&D at
- 8 Brown & Williamson.
- 9 Q. And who is D. M. Holmes?
- 10 A. He was a scientist that worked in product
- 11 development for a period of time at Brown &
- 12 Williamson. He subsequently left.
- 13 Q. Now sir, I'm going to show you what's previously
- 14 been marked as Plaintiffs' Exhibit 968. This is a
- 15 memo that you and I chatted about during your first
- 16 deposition; right?
- 17 A. I don't remember this one, but we chatted about
- 18 quite a lot, so could well have done.
- 19 Q. All right. Well Exhibit 968 --
- 20 A. Yeah.
- 21 Q. -- for the record begins with Bates number
- 22 650511308; right?
- 23 A. Right.
- 24 Q. And it says in the third paragraph, "The amount
- 25 of free nicotine in smoke is thought related to

- 1 cigarette impact and immediate pain sensation
- 2 experienced upon inhalation, therefore free nicotine
- 3 is a likely contributor to cigarette strength and
- 4 short-term smoker satisfaction.
- 5 Long-term...satisfaction is, at least in part,
- 6 derived from the total nicotine delivery (free and
- 7 bound)"; right?
- 8 MR. McCORMICK: "Right" that that's what it
- 9 says?
- 10 A. Yes, that's what it says.
- 11 Q. Now sir, isn't it true that that particular
- 12 statement was the working hypothesis of Brown &
- 13 Williamson's scientists who were addressing the issue
- 14 of increased nicotine transfer in cigarettes up to
- 15 the day that the Food and Drug Administration in this
- 16 country asserted authority over cigarettes as drugs?
- 17 A. Well and let's take it in two parts. I don't --
- 18 And we're trying to save time down the road.
- 19 I don't think there's any disagreement in this
- 20 impact sensation, this short-term sensation is
- 21 somehow associated with nicotine in the pH of smoke.
- 22 In fact that smoke pH there isn't any free nicotine.
- 23 But associated with nicotine smoke pH there's enough
- 24 empirical data to show that this impact sensation is
- 25 correlated with those, but I say it's not free

- 1 nicotine because it just doesn't exist at that smoke
- 2 pH.
- 3 (Interruption by the reporter.)
- 4 THE REPORTER: We have to go off the record
- 5 and change tape.
- 6 (Recess taken from 4:12 to 4:21 p.m.)
- 7 BY MS. WIVELL:
- 8 Q. Sir, you would agree that in 1989 --
- 9 MR. McCORMICK: Excuse me, I'm sorry. The
- 10 witness was in the middle of an answer at the end of
- 11 the last -- right before we broke.
- 12 Could I ask the court reporter to read the
- 13 partial answer.
- 14 (Record read by the reporter.)
- MR. McCORMICK: Is there anything you
- 16 wanted to add to the discussion of that paragraph?
- 17 THE WITNESS: Well that was the -- I
- 18 believe Ms. Wivell had asked me about both sentences
- 19 in the paragraph and so far I'd only responded to the
- 20 first sentence. If she wants me to respond to the
- 21 second or third I will, or we can -- because I've
- 22 really forgotten what your question was.
- 23 Q. All right. Well let me do it this way.
- 24 Sir, in 1989 you hosted a conference for
- 25 representatives of British-American Tobacco companies

- 1 from throughout the world; right?
- 2 A. Likely.
- 3 Q. Well you hosted an Ammonia Technology
- 4 Conference; right?
- 5 A. Okay.
- 6 Q. Didn't you?
- 7 A. Well, I don't have perfect recall. If you show
- 8 me a document it's so much easier for me.
- 9 Q. Sir, showing you what's been marked as Exhibit
- 10 183, this is a copy of the "Ammonia Technology
- 11 Conference Minutes" from the conference you hosted in
- 12 Louisville in 1989; right?
- 13 A. Right.
- 14 Q. And you and I have chatted about this document
- 15 at length before, haven't we?
- 16 A. I don't remember the length, but we talked about
- 17 it I'm sure.
- 18 Q. All right. And one of the things that Brown &
- 19 Williamson has done to its cigarettes that it sold in
- 20 Minnesota, it has applied ammonia technology; right?
- 21 A. To most of its brands sold throughout the United
- 22 States, yes.
- 23 Q. Which of its brands sold throughout the United
- 24 States has Brown & Williamson applied ammonia
- 25 technology to?

- 1 A. Well, it would depend on the year and the brand
- 2 and Brown & Williamson could supply you with the
- 3 detailed information, but roughly speaking around
- 4 this sort of period of time most of the non-menthol
- 5 brands, most but not all, had it. In later years
- 6 probably virtually all the non-menthol brands had
- 7 it. I'm just not sure the state in the menthol
- 8 brands because it was not in them or in them very
- 9 little at the time of my retirement and I'm just not
- 10 quite sure what the situation is as of today.
- 11 Q. When did Brown & Williamson begin using ammonia
- 12 technology for its marketed cigarettes?
- 13 A. Again that's a matter of record, but I would say
- 14 '83, '84 we were probably beginning to try.
- 15 Q. All right.
- 16 A. And let me just back up slightly. If we're
- 17 talking about ammonia technology in very broad terms,
- 18 which would even include the use -- addition of
- 19 diammonium phosphate as part of the casing, I think
- 20 that was in the $\ensuremath{\text{--}}$ some of the products we sold
- 21 internationally, such as Kent, from the time we
- 22 acquired that brand from Lorillard.
- 23 Q. All right. Well sir, diammonium phosphate has
- 24 also been used in cigarettes that have been sold
- 25 domestically here in the United States by Brown &

- 1 Williamson; right?
- 2 A. Yes.
- 3 Q. When did diammonium phosphate begin to be used
- 4 by Brown & Williamson in cigarettes that it sold here
- 5 in Minnesota?
- 6 A. Well, again it's a matter of record but I'm
- 7 saying around '83, '84 we probably started putting
- 8 diammonium phosphate into some of the reconstituted
- 9 tobacco.
- 10 Q. Now diammonium phosphate is only one method that
- 11 Brown & Williamson has utilized to ammoniate its
- 12 marketed cigarettes; right?
- 13 A. Well "ammoniate" may be a word we've used, but
- 14 the -- "ammonia chemistry" I think is a better word
- 15 to use, that there is certainly more -- more ways
- 16 other than adding diammonium phosphates to cigarettes
- 17 to use ammonia in processing of tobacco materials to
- 18 produce flavorful compounds.
- 19 Q. Sir, one of the reasons that Brown & Williamson
- 20 has used diammonium phosphate and other ammonia
- 21 compounds, including urea, is to improve nicotine
- 22 transfer of its cigarettes; isn't that true?
- 23 A. Well, I think some people thought that that
- 24 occurred, but in fact I -- more definitive in recent
- 25 work shows it doesn't have any -- any effect unless

- 1 it's through slowing down the burn rate and therefore
- 2 increasing the puff number but, I mean, it's a
- 3 marginal effect.
- 4 Q. Well sir, these notes, Exhibit 187 or, I'm
- 5 sorry.
- 6 These notes, Exhibit 183, of the ammonia
- 7 conference indicate that at the time of this
- 8 conference the people who collected together to
- 9 attend were told by Brown & Williamson employees that
- 10 one of the effects of ammonia technology on
- 11 cigarettes was to improve nicotine transfer; right?
- 12 A. Yeah, and -- and it does, not to any great
- 13 degree. It's -- It does, but it's inconsequential.
- 14 Q. Well sir, we have looked -- I'm sorry. Strike
- 15 that.
- 16 Can you turn to the page of Exhibit 183 that
- 17 ends with Bates number 049. There is a chart that
- 18 was presented to the conference attendees concerning
- 19 nicotine efficiencies versus CPCL content; right?
- 20 A. Right.
- 21 Q. CPCL at Brown & Williamson contains ammonia,
- 22 doesn't it?
- 23 A. Yeah.
- 24 Q. And sir, this document shows that nicotine
- 25 transfer essentially shoots off the top of the chart

- 1 almost when CPCL content of cigarettes is increased;
- 2 right?
- 3 A. Okay. We're looking at, as the way the scale of
- 4 the graph is is from 15 percent to 18.5, it's not
- 5 like it's going from zero to a hundred so, you know,
- 6 normally it would make -- say 15 percent transfer
- 7 would be -- well it doesn't make a huge difference
- 8 and it's making a difference because it's changing
- 9 the puff number. And when I answered before, and I
- 10 should make sure I'm really crystal clear here so I'm
- 11 not misleading you or myself or anyone else, the
- 12 addition of CPCL, which is a reconstituted tobacco
- 13 made with the ammonia technology, causes the
- 14 cigarette burn rate to go down you get an increased
- 15 number of puffs, therefore you get more tar and more
- 16 nicotine unless you counteract that by filtering
- 17 more, which is in fact what we do.
- 18 Q. Well sir, you would agree --
- 19 A. So you get back to where you started.
- 20 Q. Sir, you would agree that bound nicotine is a
- 21 larger molecule than unbound nicotine, wouldn't you?
- 22 A. Well if we mean -- Golly, depends what you mean
- 23 by "bound nicotine." But it's -- it's doubly charged
- 24 if it's diprotonated, and I suppose it is but, you
- 25 know, we're down in atomic science and I'm not sure

- 1 where -- if I can answer this very sensibly.
- 2 Q. Well a monoprotonated molecule of nicotine is
- 3 smaller than a bound or diprotonated molecule of
- 4 nicotine; right?
- 5 A. Well, a nicotine molecule is a nicotine
- 6 molecule, and then it becomes an ion as soon as it's
- 7 protonated and then diprotonated, and golly, I'm not
- 8 enough of a whatever it is to tell you what their
- 9 different sizes are.
- 10 Q. So sir, is it beyond your area of competence to
- 11 testify about whether free nicotine gets absorbed
- 12 faster in the lower portion or the alveoli of the
- 13 lung?
- 14 A. Well it's not my competence. I think that when
- 15 nicotine gets absorbed down there from these little
- 16 aerosol particles it's -- a little particle is
- 17 immediately bathed in physiological fluid which is
- 18 around a pH of 7.2, so there will be a small portion
- 19 of unbound nicotine and then some protonate and then
- 20 diprotonated and the unbound goes through and then
- 21 dissociation goes on and on. But I don't think that
- 22 the -- the pH of what lands actually has much effect
- 23 on how fast it's absorbed.
- 24 Q. Sir, you really don't know one way or the other,
- 25 do you, whether the size of the nicotine molecule

- 1 affects the rate of absorption by the body.
- 2 A. Well the science doesn't have anything to do
- 3 with it, it's whether it's protonated or unprotonated
- 4 and the degree --
- 5 (Interruption by the reporter.)
- 6 A. The size doesn't really have anything to do with
- 7 it. Once you're down at the molecular level it's
- 8 going to be more, you know, in the physiological
- 9 fluid and it all happens very fast and I don't think
- 10 it's going to happen any faster or slower depending
- 11 on what the pH of that little particle was that
- 12 landed there.
- 13 Q. But sir, that's not your area of competence, is
- 14 it?
- MR. McCORMICK: When you say his "area of
- 16 competence," are you talking about training or
- 17 experiments which he's personally done versus --
- MS. WIVELL: Yes.
- 19 MR. McCORMICK: -- what his role was at the
- 20 company?
- 21 Q. That's not your area of professional training or
- 22 competence, is it, sir?
- 23 A. I'm not sure that it's anyone's specifically,
- 24 but in terms of chemistry and some sort of
- 25 rudimentary scientific knowledge, I -- I think what I

- 1 have said is quite accurate.
- 2 Q. But you would agree that Brown & Williamson has
- 3 known for years that smoking impact and the sensation
- 4 that a smoker gets from taking a cigarette has to do
- 5 with the amount of free nicotine in the cigarette
- 6 smoke.
- 7 A. No. I mean that -- that term is used loosely
- 8 but it's incorrect. If you go back to the
- 9 British-American Tobacco Company reports, we talked
- 10 about this at great length last time. You've shaken
- 11 this stuff up in chloroform, and what comes out in
- 12 chloroform is called, quote, free nicotine but it
- 13 isn't really. And you showed me earlier that --
- 14 something this afternoon, and I said in my previous
- 15 deposition. But what I'm trying to do is give you
- 16 the best accurate facts as known today.
- 17 Q. But sir, Brown & Williamson ammoniated its
- 18 cigarettes with the idea in mind to increase
- 19 nicotine-transfer efficiency of the nicotine in its
- 20 cigarette products; isn't that true?
- 21 A. No, we did it to try and make them taste like
- 22 Marlboro.
- 23 Q. Well sir, one of the reasons that you tried to
- 24 make them taste like Marlboro is because Marlboro had
- 25 a higher pH and had an increased nicotine-transfer

- 1 efficiency; isn't that true?
- 2 MR. FRYKBERG: Object to form.
- 3 (Interruption by the reporter.)
- 4 A. Well, that was part of our hypothesis but, I
- 5 mean, in fact it's -- that's not the case. The fact
- 6 is that just people preferred the taste of Marlboro.
- 7 Q. Well sir, going back to Exhibit 183, if we turn
- 8 to the page that ends with Bates number 030, there is
- 9 a comparison of blend, smoke ammonia and
- 10 nicotine-transfer efficiency of Viceroy, Marlboro and
- 11 Winston; right?
- 12 A. I'm sorry, what page are we on?
- 13 Q. 030.
- 14 A. Yes.
- 15 Q. And sir, this chart shows that Marlboro had a
- 16 nicotine-transfer efficiency of 17.8 percent, didn't
- 17 it?
- 18 A. Yes.
- 19 Q. It was higher than Viceroy and Winston, wasn't
- 20 it?
- 21 A. Well Winston doesn't give any data. Higher than
- 22 Viceroy.
- 23 Q. Now sir, you would agree that Brown &
- 24 Williamson, based on the information it had
- 25 concerning Marlboro cigarettes, spent millions and

- 1 millions of dollars to try and copy the taste and
- 2 impact sensation that Marlboro presented to a
- 3 smoker.
- 4 A. Well we tried to get there and then we tried to
- 5 get something they would like even better, but we
- 6 thought if we could get there then we'd at least be
- 7 on the way.
- 8 Q. And that's because Marlboro's sales had
- 9 skyrocketed up and Brown & Williamson's cigarette
- 10 sales had gone down; right?
- 11 A. That's right.
- 12 Q. And Brown & Williamson reverse engineered
- 13 Marlboro to try and figure out why Marlboro smokers
- 14 like Marlboro better than Brown & Williamson's
- 15 cigarettes; right?
- 16 A. Well hang on a second. We reverse engineered to
- 17 try and understand how Philip Morris -- what
- 18 ingredients they used to make Marlboro; the
- 19 hypothesis being that it was the taste of Marlboro,
- 20 rather than the advertising, which was causing the
- 21 whole thing. Of course we could have been terribly
- 22 wrong. It might have been all the advertising, but I
- 23 don't know.
- 24 Q. But you found out that the secret of Marlboro
- 25 was ammonia; right?

- 1 MR. FRYKBERG: Object to form.
- 2 A. Well, the -- a large part of getting the
- 3 characteristic taste sensations of Philip Morris
- 4 cigarettes, not just Marlboro but most of their other
- 5 brands as well, was to use this ammonia technology in
- 6 the preparation of reconstituted tobacco, which
- 7 basically what that was doing was producing some very
- 8 flavorful compounds by its reaction with sugar.
- 9 Q. And you would agree that British-American
- 10 Tobacco Company worldwide has instituted ammonia
- 11 technology among all of its group tobacco companies;
- 12 isn't that true, sir?
- MR. KOMAR: Object to form.
- 14 A. Well, you know, I can't speak for all of them
- 15 and it works very well in American blended-type
- 16 cigarettes but I'm not sure that it -- it works
- 17 particularly well in flue-cured cigarettes or some
- 18 other kinds of cigarettes that are smoked around the
- 19 world but --
- 20 Q. Are you familiar with Worldwide Best, sir?
- 21 A. Well it's a project that's been running for some
- 22 time which was trying to develop a cigarette to
- 23 compete with Marlboro worldwide, yes.
- 24 Q. And isn't it true that the tobacco member
- 25 companies of British-American Tobacco -- tobacco

- 1 group have spent literally tens of millions of
- 2 dollars in order to institute ammonia technology to
- 3 try and come up with a cigarette worldwide that would
- 4 beat Marlboro?
- 5 A. You know, I don't know how many millions of
- 6 dollars, but certainly that has been a very major
- 7 emphasis in R&D is -- yeah.
- 8 Q. And one of the reasons that Brown & Williamson
- 9 and the other members of the B.A.T. group company did
- 10 this was to try and increase the nicotine-transfer
- 11 efficiency of their cigarettes; isn't that true?
- 12 A. No, no, that's -- was a hypothesis and part of
- 13 the thing, but it turns out it's got nothing to do
- 14 with it. The important thing are these flavorful
- 15 compounds that are generated.
- 16 Q. Well sir, that was a hypothesis that was
- 17 discussed with all of these British-American Tobacco
- 18 Company representatives when you brought them all
- 19 together in Louisville in 1989; right?
- 20 A. Well I think that if -- Somewhere, and this is a
- 21 huge great document, but somewhere, it may not be
- 22 this one, it may be a report put together, but it
- 23 says that this ammonia technology is -- is doing what
- 24 naturally occurs in cigarettes anyway, that this --
- 25 this reaction is some of the basic compounds with

- 1 sugars during aging and blending and that this is
- 2 producing the characteristic American blend flavor
- 3 which Philip Morris managed to enhance, and at least
- 4 in our view was one of the contributors to the
- 5 success of Marlboro.
- 6 Q. Well sir, isn't it true that at this conference
- 7 that's talked about in Exhibit 183, nicotine-transfer
- 8 efficiency due to ammoniation was one of the topics
- 9 that was discussed with all of the conferees who came
- 10 to the conference?
- 11 MR. McCORMICK: Could you, in the interest
- 12 of time, direct him to a portion of this, if that's
- 13 the case?
- 14 Q. Well, sir, directing your attention to page 017,
- 15 there is a discussion in the center on the main
- 16 effects of ammonia technology; right?
- 17 A. Sure and --
- 18 Q. And it says in number -- point number 2,
- 19 "Improved nicotine transfer," doesn't it?
- 20 A. Right. And point number 1 is "Enhanced natural
- 21 flavor/body" that I've been talking about. This
- 22 improved nicotine transfer, it's -- it's a fact, it's
- 23 not a huge amount, and the whole -- this whole
- 24 business of this nicotine-transfer efficiency which I
- 25 admit Brown & Williamson, B.A.T. sort of had a bee in

- 1 their bonnet about for quite some time, is a real red
- 2 herring because the amount of nicotine that comes out
- 3 of the end of the cigarette is controlled largely by
- 4 your filter and the choice of cigarette paper.
- 5 Q. Well sir, isn't it true that --
- 6 A. It doesn't -- I'm sorry.
- 7 MR. McCORMICK: Go ahead, sir, and finish.
- 8 A. But if I could just finish.
- 9 Improved nicotine transfer has nothing to do
- 10 with whether or not somebody likes a cigarette. All
- 11 the nicotine transfer leads to is what is the number
- 12 that's going to be derived by the standard smoking.
- 13 Whether people like the cigarette is this whole
- 14 complex of flavor and everything else that goes into
- 15 the smoke.
- 16 Q. Sir, isn't it true that this bee was in Brown &
- 17 Williamson and British-American Tobacco's bonnet
- 18 about nicotine-transfer efficiency being improved by
- 19 ammonia right up to the day that the FDA asserted
- 20 authority over cigarettes as drugs?
- 21 MR. McCORMICK: I think he said
- 22 British-American Tobacco Company. You can answer.
- 23 A. Well, okay. The bee was in some of my
- 24 colleague's bonnets and my own bonnet from time to
- 25 time. I'm not sure it was the day I retired -- I

- 1 really don't think the FDA desire to regulate
- 2 nicotine was the thing that caused any light bulbs to
- 3 flash. As I say, it was a red herring.
- 4 Q. Well sir, isn't it true that if British American
- 5 -- I'm sorry, strike that.
- 6 Isn't it true that if Brown & Williamson
- 7 admitted to the FDA that it intended to use ammonia
- 8 technology to increase the transfer of nicotine, that
- 9 that would mean it would have to submit voluntarily
- 10 to the FDA's authority to regulate cigarettes as
- 11 drugs?
- 12 A. Well no. I mean, the -- the mere act of putting
- 13 on a filter or changing the filter efficiency of a
- 14 cigarette changes the nicotine-transfer efficiency.
- 15 I mean nicotine-transfer efficiency is one of the
- 16 most basic parts of cigarette design.
- 17 Q. And you would agree that ammonia changes the
- 18 nicotine-transfer efficiency of cigarettes, doesn't
- 19 it?
- 20 A. No, it all depends how -- If you're using this
- 21 ammonia technology to make this denser reconstituted
- 22 tobacco that certainly does because it changes the
- 23 burn rate. Simple addition of diammonium phosphate
- 24 may slow the burn rate down a little bit, I'm not
- 25 sure. But, you know, it's not a big deal, and as I'm

- 1 tying to point out, the filter, the degree of
- 2 ventilation, the cigarette paper has a much, much,
- 3 much greater effect on nicotine-transfer efficiency
- 4 and is an every day cigarette design tool to make the
- 5 cigarette conform to a particular tar level.
- 6 Q. Sir, I understand that those are factors, but
- 7 you would agree, wouldn't you, sir, that ammoniation
- 8 of the tobacco in nicotine affects the transfer
- 9 efficiency of the nicotine in the tobacco?
- 10 A. As you stated your question, no.
- 11 Q. So you just disagree with that hypothesis;
- 12 right?
- 13 A. No, I said "as you stated your question," which
- 14 if you'd like to get it read back you'll realize why
- 15 I disagreed with it.
- 16 Q. All right. Why did you disagree with it, sir?
- 17 A. Let's ask the reporter to read it back.
- 18 (Record read by the reporter.)
- 19 Q. Let me restate the question.
- 20 I understand those are factors, sir, but you
- 21 would agree, wouldn't you, that the ammoniation of
- 22 the nicotine in tobacco affects the transfer
- 23 efficiency of that nicotine.
- 24 A. Just to help you, Ms. Wivell, the -- you said
- 25 "the ammoniation of the nicotine," and the nicotine

- 1 doesn't get ammoniated, the --
- 2 Q. The tobacco gets ammoniated, doesn't it, sir?
- 3 A. Well the -- The ammoniation is a reaction
- 4 largely of nicotine with the sugars, and if you just
- 5 took some flue-cured tobacco and ammoniated it there
- 6 would be this reaction of ammonia with the sugars to
- 7 produce these flavorful compounds, and I don't think
- 8 that, per se, would have any effect on the burn
- 9 rate. It's when you somehow are using the ammonia
- 10 technology or the ammonia salts to produce a
- 11 slower-burning material, such as some kinds of
- 12 reconstituted tobacco, that then there is an increase
- 13 in both tar and nicotine because of a diminution in
- 14 burn rate.
- 15 Q. And sir, you would agree that one of the reasons
- 16 that Brown & Williamson used ammonia on its tobacco
- 17 was to try and free up more nicotine for the smoker,
- 18 wouldn't you?
- 19 A. Well again, you know, that's a hypothesis that
- 20 may have been put in, but in fact the amount of
- 21 nicotine that gets to the smoker is really controlled
- 22 in very large part by the cigarette filter and the --
- 23 the design of the cigarette and much -- not really at
- 24 all by this ammoniation.
- 25 Q. Well sir, the ammoniation affecting the amount

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 of nicotine that is freed up and transferred to the
- 2 smoker, that was a working hypothesis at Brown &
- 3 Williamson while you were there, wasn't it?
- 4 A. It was certainly a hypothesis of Chakraborty's,
- 5 yeah.
- 6 (Interruption by the reporter.)
- 7 A. Hypothesis of Chakraborty's,
- 8 C-H-A-K-R-A-B-O-R-T-Y.
- 9 Q. And that was a hypothesis that was presented to
- 10 all the people who attended the nicotine conference
- 11 that is referred to in Exhibit 183, isn't it?
- MR. McCORMICK: Again, do you have a
- 13 reference there to the report, Ms. Wivell?
- 14 A. Well, I don't know. I think we're probably kind
- 15 of all repeating ourselves, but this summary page
- 16 Chakraborty's says there are main effects of ammonia
- 17 disposition were the enhanced natural flavor, the
- 18 improved nicotine transfer, the reduced irritation
- 19 and the superior paper reconstituted.
- 20 Q. And sir, it was also the hypothesis that was
- 21 presented by Dr. Werner Bass of B.A.T. companies
- 22 British -- or I'm sorry, German subsidiary, isn't
- 23 it?
- MR. McCORMICK: Again, can you provide the
- 25 witness a reference?

- 1 MR. KOMAR: Object to form.
- 2 (Interruption by the reporter.)
- 3 A. I'm sorry, I can't think of somebody called
- 4 Werner Bass so I do need a reference.
- 5 Q. I'm sorry, Werner Hass.
- 6 A. I think I still need a reference.
- 7 Q. Could you turn to page 091.
- 8 A. Okay, yes. Werner Hass.
- 9 Q. And he is from BATCo's German subsidiary?
- 10 A. BAT Cigaretten Fabriken.
- 11 Q. That's right, isn't it, sir, it's
- 12 British-American Tobacco Company -- or B.A.T.
- 13 Industry's German subsidiary; right?
- 14 A. Well it's the German arm of -- Well, it's as it
- 15 says, BATCF. Now what are we looking for here?
- 16 Q. All right. Well sir, he presented a paper at
- 17 this conference entitled "Effects of Ammonia on
- 18 Nicotine Distribution in Cigarette Blends"; right?
- 19 A. Yes.
- 20 Q. And one of the things he talked about was the
- 21 fact that "ammonia and nicotine transfer, readily
- 22 ammonia faster"; right?
- 23 A. Right.
- 24 Q. And sir, isn't it true that throughout the
- 25 B.A.T. group at the time this conference was held it

- 1 was believed that ammoniation affected an increased
- 2 nicotine transfer?
- 3 MR. KOMAR: Object to form.
- 4 A. Again let's -- I don't know what you mean by
- 5 "throughout the B.A.T. group." Let's talk, if you
- 6 don't mind, because largely the people that worked on
- 7 this are the people in British-American Tobacco
- 8 Company in England, the people in Louisville Brown &
- 9 Williamson, and the people at B.A.T. Cigaretten
- 10 Fabriken who worked on this, and Werner Hass was
- 11 looking at how ammonia and nicotine transfer amongst
- 12 the various blend components once you put a cigarette
- 13 together; so you have oriental tobacco and you have
- 14 flue-cured tobacco and you have burly tobacco, and
- 15 burly tobacco naturally contains nicotine -- sorry,
- 16 naturally contains ammonia as well as nicotine. So
- 17 when you put a blend together, leave -- not doing any
- 18 ammoniation, but just burly tobacco, flue-cured
- 19 tobacco and oriental tobacco, which is what American
- 20 and German cigarettes are made from, ammonia
- 21 transfers from the burly tobacco to the flue-cured
- 22 tobacco and then reacts with the sugars there.
- 23 Q. Sir, let me ask you this question. You
- 24 concluded, as a result of your investigations, that
- 25 five of the six major U.S. cigarette manufacturers

- 1 used ammonia technology in at least some of their
- 2 marketed cigarettes; right?
- 3 A. Right.
- 4 MS. WIVELL: I have nothing further.
- 5 MR. McCORMICK: Any other questions?
- 6 MR. CAMPF: Let me just make a statement
- 7 for the record before we go off. This is Brian Campf
- 8 for the New York plaintiffs. This deposition was
- 9 cross-noticed in the New York actions, and as I
- 10 understand it, was served upon counsel.
- 11 Mr. McCormick has informed me today that he did
- 12 not receive notice of our cross-notice until this
- 13 morning and that the witness is not available
- 14 tomorrow morning at the time for which our deposition
- 15 in the New York cases was to continue from today, and
- 16 Mr. McCormick has kindly agreed that we will work to
- 17 reschedule the deposition of this witness at a
- 18 mutually convenient time.
- 19 MR. McCORMICK: I agree. You don't have
- 20 any questions about the 30.02 portion?
- 21 MR. CAMPF: No, I'll carry forward with my
- 22 questions when we again reschedule this deposition.
- MR. McCORMICK: Well you have an
- 24 opportunity to question now. Do you have anything at
- 25 this point?

- 1 MR. CAMPF: Not now, but I'm reserving my
- 2 rights to carry forward when we commence for the New
- 3 York cases.
- 4 MR. McCORMICK: All right.
- 5 MS. WIVELL: Excuse me, Steve, are you
- 6 going to ask some questions?
- 7 MR. McCORMICK: Yes, I am.
- 8 MS. WIVELL: Can we take a brief break?
- 9 MR. McCORMICK: Surely, of course.
- 10 (Discussion off the stenographic record.)
- 11 EXAMINATION
- 12 BY MR. McCORMICK:
- 13 Q. Mr. Reynolds, going back to early in the
- 14 questioning today by Ms. Wivell, you were asked about
- 15 a series of research efforts that were undertaken on
- 16 behalf of British-American Tobacco Company by the
- 17 Battelle facility in Switzerland. Do you recall --
- 18 A. Yes.
- 19 Q. -- that general area of questioning?
- 20 And in particular a series of studies sometimes
- 21 referred to as HIPPO, MAD HATTER and a document
- 22 referred to later as "The Fate of Nicotine in the
- 23 Body." Do you recall generally having testified
- 24 about that both today and in your previous
- 25 deposition?

- 1 A. Today. I don't recollect the previous one.
- 2 Q. All right. With respect to the work on nicotine
- 3 that was done by the Battelle organization for
- 4 British-American Tobacco Company back in late nine --
- 5 in the late 1950s and early 1960s, was that work
- 6 which you described as premature in the form in the
- 7 reports that were ultimately submittedby Battelle,
- 8 was that work continued in the U.K. following the
- 9 completion of those research reports?
- MS. WIVELL: Objection.
- 11 A. My understanding was that Armitage, the
- 12 criticizer who is head of the Tobacco Research
- 13 Council labs in Harrogate, England, did a lot more
- 14 work in the area of the interaction of nicotine with
- 15 animals, I think it was both cats and possibly dogs,
- 16 and that all this stuff was published in the
- 17 scientific literature.
- 18 Q. And by Tobacco Research Council in Harrogate,
- 19 the Tobacco Research Council in the United Kingdom
- 20 was a cooperative industry research program; is that
- 21 correct?
- MS. WIVELL: Objection.
- 23 A. Well, it was funded by the industry. I believe
- 24 that it was -- I'm trying to think -- independent. I
- 25 mean the industry didn't dictate what it did, but the

- 1 industry gave it money to do stuff.
- 2 Q. "Cooperative" in the sense that it was funded
- 3 by, among other people, British-American Tobacco
- 4 Company.
- 5 MS. WIVELL: Objection.
- 6 A. That's correct.
- 7 Q. And to your knowledge, was that work done on the
- 8 subjects that were -- that had been discussed and
- 9 explored preliminary by -- preliminarily by Battelle,
- 10 was that work published in the open scientific
- 11 literature?
- 12 A. I can recollect some specific papers by Armitage
- 13 on nicotine absorption and the fate of nicotine,
- 14 reaction of nicotine, I'm not sure if all word for
- 15 word was but, I mean, the general area was published.
- 16 Q. Now Mr. Reynolds, you were shown earlier a
- 17 document that was marked as Defendants Exhibit 552
- 18 that was a document, two-and-a-half-page document by
- 19 Hasselbach and Libert called "A TENTATIVE HYPOTHESIS
- 20 ON NICOTINE ADDICTION," and I'm going to put that in
- 21 front of you again if I may.
- During the course of this short interrogation
- 23 this afternoon that term "hypothesis" has been used
- 24 many, many times. Could you explain for the court
- 25 and the jury what is meant by -- in science by the

- 1 use of the term "hypothesis"?
- MS. WIVELL: Objection.
- 3 A. Well, a hypothesis is coming up with a possible
- 4 explanation for something that can be tested
- 5 experimentally, and that's all it is. Subsequently
- 6 facts may say this explanation that we've suggested
- 7 is true or may say it's not true. Let me give you a
- 8 -- a real concrete example which I think would sink
- 9 home to most of us.
- 10 For many years it was not just a hypothesis, it
- 11 was thought that stress was what was causing stomach
- 12 ulcers, but in fact about seven or eight years ago an
- 13 Australian physician showed that it was an ulcer and
- 14 people laughed at him.
- 15 Q. It was an ulcer?
- 16 A. Bacterium causing stomach ulcers.
- 17 And so this hypothesis about stress was just
- 18 totally wrong and eventually it was factually proven
- 19 it was a bacterium, so that's an example.
- 20 Q. All right. In the normal scientific usage when
- 21 a scientist says that he or she has developed a
- 22 hypothesis, does that mean that that scientist
- 23 believes that he or she has found the scientific
- 24 answer to the question?
- MS. WIVELL: Objection.

- 1 A. They -- They hope they have but they -- as I
- 2 say, it's a hypothesis because they don't know
- 3 whether it is or isn't the answer to the question
- 4 until they've done the experiment to ascertain that.
- 5 Q. So a hypothetical --
- 6 Would it be fair to say that a hypothesis is, by
- 7 definition, a tentative conclusion?
- 8 MS. WIVELL: Objection.
- 9 A. Well no, I don't think it's even -- it's not a
- 10 tentative conclusion, it's -- it's a possible
- 11 explanation of something that's occurring and there's
- 12 nothing at all conclusive about it.
- 13 Q. All right. And with respect to Plaintiffs'
- 14 Exhibit 552, "A TENTATIVE HYPOTHESIS OF NICOTINE
- 15 ADDICTION," is there any data contained in this two
- 16 and a half pages? Does this report purport to be the
- 17 result of a study or the interpretation of some
- 18 findings that were done?
- 19 MS. WIVELL: Objection.
- 20 A. Well let me -- I'm not even sure if I'm going to
- 21 answer the question you asked, but a tentative
- 22 hypothesis itself is a bit redundant. If it's a
- 23 hypothesis, it's tentative. But when -- They're
- 24 talking about some facts, they say laboratory
- 25 experiments with rats, injection of nicotine induces

- 1 a marked reduction in food intake but, you know, I'm
- 2 not quite sure how that then all -- all balances
- 3 together, and I don't even -- I don't even know
- 4 specifically what they were meaning by "nicotine
- 5 addiction." But I -- I don't think, you know, anyone
- 6 really considers nicotine, per se, to be addictive.
- 7 Q. Now you were also shown, Mr. Reynolds, a
- 8 document that was marked for identification as
- 9 Plaintiffs' Exhibit 475, and just in the interests of
- 10 time I believe you'll recollect this, you were
- 11 referred to a paragraph in the middle of a
- 12 discussion, the heading of that discussion a couple
- 13 of pages earlier was titled "Tomkins' Theory." Do
- 14 you recall that?
- 15 A. Yes.
- 16 Q. And that --
- 17 Is that document, or particularly that section
- 18 of the document a recitation or somebody's recitation
- 19 or reiteration of something called Tomkins' theory?
- MS. WIVELL: Objection.
- 21 A. Well yes, it is, and I -- and I thought I'd --
- 22 I'd hoped I'd made that clear when Ms. Wivell asked
- 23 me the question earlier.
- 24 Q. And I think you had, but my question really is
- 25 going to be: Who is Tomkins?

- 1 A. Well, some psychologist that had a theory about
- 2 smoking motivation, certainly not a British-American
- 3 Tobacco or Brown & Williamson employee, some
- 4 presumably psychologist or psychiatrist, but I don't
- 5 know who -- who Tomkins is.
- 6 Q. Okay. But this document in this respect
- 7 purports to be a recitation of something that had
- 8 been published somewhere by someone named Tomkins.
- 9 MS. WIVELL: Objection.
- 10 A. Well that's my understanding, yes.
- 11 Q. Ms. Wivell asked you about somebody who I
- 12 believe she characterized as a -- Well, let me start
- 13 that over.
- 14 Ms. Wivell asked you about somebody by the name
- 15 of Dr. M. A. H. Russell who Ms. Wivell characterized
- 16 as a -- a consultant or asked you if he had been a
- 17 consultant. Can you explain who Dr. M. A. H. Russell
- 18 was in the United Kingdom?
- 19 A. Well I think he still is, I may be wrong.
- 20 Q. And still is.
- 21 A. He's a leading figure in the smoking-and-health
- 22 world. I believe he's at the Maudsley Institute of
- 23 Psychiatry --
- 24 (Interruption by the reporter.)
- 25 A. -- Maudsley Institute of Psychiatry which is

- 1 part of the University of London, he is dedicated to
- 2 the view that smoking is a major cause of disease,
- 3 that smoking is addictive. He is a -- I don't mean
- 4 to use it unkindly, but he is as antitobacco as
- 5 anyone I can think of.
- 6 Q. Mr. Reynolds, at the end of your interrogation
- 7 by Ms. Wivell today she asked you a series of
- 8 questions on the subject of free nicotine which I
- 9 believe the record will reflect was discussed in
- 10 great detail and for several hours during the course
- 11 of your previous deposition, and I don't want to or
- 12 mean to reiterate the question -- all of the
- 13 questions that I asked you about that subject when I
- 14 had a chance to ask you the last time, but let me
- 15 just sum up to make sure we are clear on this
- 16 subject.
- Does the addition of ammonia to -- as it was in
- 18 fact incorporated commercially by Brown & Williamson,
- 19 as opposed to what laboratory experiments might have
- 20 shown, does the addition of ammonia as Brown &
- 21 Williamson utilized it commercially, have any affect
- 22 on the amount of nicotine that is available to and
- 23 absorbed in the lungs of the smoker?
- MS. WIVELL: Objection.
- 25 A. No.

- 1 MR. McCORMICK: That's all I have.
- 2 MS. WIVELL: All right. I would like to
- 3 take a break now.
- 4 MR. McCORMICK: Of course.
- 5 THE REPORTER: Off the record, please.
- 6 (Recess taken from 5:03 to 5:09 p.m.)
- 7 EXAMINATION
- 8 BY MS. WIVELL:
- 9 Q. Sir, you spoke as -- in response to Mr.
- 10 McCormick's questions about the studies of project
- 11 HIPPO, project MAD HATTER and the study entitled "The
- 12 Fate of Nicotine in the Body"; right?
- 13 A. Yes.
- 14 Q. You didn't mean to imply to the ladies and
- 15 gentlemen of the jury that someone named Armitage did
- 16 that work, did you?
- 17 A. No.
- 18 Q. Armitage published his work, didn't he?
- 19 A. Yes.
- 20 Q. And these studies that were done as part of
- 21 Battelle's work on project HIPPO, project MAD HATTER
- 22 and the study entitled "The Fate of Nicotine in the
- 23 Body" were never published by British-American
- 24 Tobacco Company, were they?
- 25 A. No.

- 1 Q. You didn't mean to imply that they were when you
- 2 were talking about Dr. Armitage publishing his work
- 3 that was done later, did you?
- 4 A. No. What I was pointing out was that the
- 5 preliminary work that was done at Battelle was kind
- 6 of expanded on at the Tobacco Research Council
- 7 laboratories, and then that was published.
- 8 Q. But just so we're clear, Dr. Armitage did not do
- 9 the work at Battelle Institute on project HIPPO,
- 10 project MAD HATTER or "The Fate of Nicotine in the
- 11 Body, " did he, sir?
- 12 A. That's correct.
- 13 Q. And sir, you would agree that the work that
- 14 British-American Tobacco Company funded on project
- 15 HIPPO, project MAD HATTER and "The Fate of Nicotine
- 16 in the Body" was never published in the scientific
- 17 literature, was it?
- 18 A. That's correct.
- 19 Q. Now sir, you also talked about Exhibit 552, Dr.
- 20 Hasselbach and Libert's hypothesis concerning
- 21 nicotine addiction; right?
- 22 A. Right.
- 23 Q. Their hypothesis was borne out, wasn't it, sir?
- 24 A. I'm sorry? I don't follow you.
- 25 Q. Well sir, you testified, and I think I've gotten

STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953

- 1 this right because I wrote it down and checked it
- 2 against our transcript, quote, no one really
- 3 considers nicotine to be addictive. Now that's not
- 4 true, is it, sir?
- 5 A. I'm sorry, no -- No one really considers
- 6 nicotine to be addictive. No, nicotine --
- 7 Q. Well sir, the surgeon general of the United
- 8 States considers nicotine to be addictive, doesn't
- 9 he?
- 10 A. Well, I mean, we don't have one right now unless
- 11 they've been confirmed, but no, nicotine --
- 12 nicotine's not addictive, otherwise it would be
- 13 leaping -- you know, everyone would be gobbling
- 14 nicotine chewing gum, nicotine patches would be
- 15 leaping off the shelves in drug stores but they're
- 16 not, no.
- 17 Q. Sir, isn't it true that the surgeon general of
- 18 the United States, in a report issued after 1964,
- 19 concluded that cigarette smoking was addictive?
- 20 A. The surgeon general's report redefined the
- 21 cigarette -- redefined "addiction" so that cigarette
- 22 smoking would fall under that new definition.
- 23 Q. And you would agree, sir, that the surgeon
- 24 general and the scientists who made up the report
- 25 that made that, quote unquote, redefinition,

- 1 concluded that cigarette smoking was addictive;
- 2 right?
- 3 A. Well sure, if you define something the way you
- 4 want to define it so that you can include a class of
- 5 something or other then, I mean it's a
- 6 self-fulfilling prophecy.
- 7 Q. Well sir, are you familiar with the testimony
- 8 that's been given in this case by Defendants' expert
- 9 witness, Dr. Peter Rowell, on the subject of whether
- 10 nicotine is addictive?
- 11 A. No.
- 12 Q. Well sir, are you familiar with the testimony he
- 13 gave to the effect that nicotine in cigarettes
- 14 produces dependence?
- MR. McCORMICK: Object to the
- 16 characterization of that testimony.
- 17 A. Okay. Let me back up. I'm not -- You know, I'm
- 18 not aware of any of the testimony he gave, so I can't
- 19 be aware of a subset of it.
- 20 Q. Well sir, are you aware that Dr. Rowell
- 21 testified that the term "dependence" and "addiction"
- 22 are synonymous and interchangeable?
- 23 MR. McCORMICK: Objection. Same
- 24 objection.
- 25 A. I am not aware of any of Dr. Rowell's testimony.

- 1 Q. So when you testified that no one really
- 2 considers nicotine to be addictive, you didn't have
- 3 Dr. Peter Rowell's expert opinions in this case in
- 4 mind, did you, sir?
- 5 MR. McCORMICK: Objection.
- 6 A. I did not have his transcript in front of me.
- 7 Well, you know, it's just common sense it's not.
- 8 Q. Sir, you did not have Defendants' --
- 9 A. No, and I didn't need it.
- 10 Q. I'm sorry, may I finish?
- 11 When you gave that testimony you did not have
- 12 Defendants' expert's opinion on the subject of
- 13 whether nicotine was dependent forming, did you,
- 14 sir?
- MR. McCORMICK: I'm going to object, this
- 16 is a mischaracterization of the testimony, unfair to
- 17 this witness to imply that this witness -- that some
- 18 other witness has given testimony when I do not
- 19 believe that that's the case that he has, and in any
- 20 event the question is asked and answered.
- 21 (Discussion off the stenographic record.)
- 22 Q. Let me repeat the question.
- When you gave that testimony you did not have
- 24 Defendants' expert's opinion on the subject of
- 25 whether nicotine was dependence forming in mind, did

- 1 you, sir?
- 2 A. Ms. Wivell, I've said three or four times I have
- 3 never seen that particular testimony so I cannot, you
- 4 know -- I can't talk about it because I've never seen
- 5 it.
- 6 Q. All right. Well let me show you.
- 7 I'm going to show you Peter Rowell's testimony
- 8 in this case and ask you if at page 134 he is asked
- 9 the question: If I change the word from addictive to
- 10 a dependence without the adjective mild, moderate or
- 11 severe in front of it, as a dependence is it your
- 12 opinion that nicotine in cigarettes is dependence
- 13 producing? And did he answer: The nicotine in
- 14 cigarettes, I would not disagree with that. I am not
- 15 sure that the evidence is really strong, but it's
- 16 probably a correct statement that the amount of
- 17 nicotine they receive from cigarettes can produce
- 18 some degree of dependence.
- 19 Did I read that correctly, sir?
- 20 A. As a dependence, is it your opinion that
- 21 nicotine in cigarettes is dependence producing? And
- 22 his answer is: The nicotine in cigarettes, I would
- 23 not disagree with that. I'm not sure that the
- 24 evidence is real strong, but it's probably a correct
- 25 statement that the amount of nicotine they receive

- 1 from cigarettes can produce some degree of
- 2 dependence.
- 3 Q. And then --
- 4 A. And -- I mean, that wasn't the question you
- 5 initially asked me at all, Ms. Wivell.
- 6 Q. And then, sir, he goes on to say, in his
- 7 opinion, addiction and dependence are used
- 8 synonymously; correct?
- 9 A. Well again, I don't have the context of this. I
- 10 was sitting next to a lady on the plane flying here
- 11 last night, never met her in -- obviously never met
- 12 her in the world before. I didn't say a word. She
- 13 says to me, "Have an Altoid. I'm addicted to
- 14 these." People use "addiction" all sorts of ways.
- MS. WIVELL: Move to strike as
- 16 nonresponsive.
- 17 Q. Sir, my question is: And then Dr. Rowell,
- 18 Defendants' expert opinion on the subject of nicotine
- 19 and a -- nicotine addiction, testified that
- 20 cigarettes -- I'm sorry -- that dependence and
- 21 addiction were synonymous; correct?
- 22 A. No, you know, I'm -- I've not seen this
- 23 document, I keep on pulling bits out of context,
- 24 misreading them, weaving here and there.
- No, I don't agree.

- 1 Q. Well sir, let me show you a sentence and ask you
- 2 if you had this in mind. He was asked: Do you have
- 3 an opinion as to whether cigarette smoking produces
- 4 withdrawal symptoms on cessation or efforts to stop?
- 5 And he said: I would -- I would say so or I would
- 6 agree. You have the transcript, I can't read it.
- 7 A. Get the right glasses here. Wrong ones.
- 8 MR. McCORMICK: What's the reference here,
- 9 Ms. Wivell?
- 10 A. Okay. This is Dr. Rowell, a -- it doesn't have
- 11 any of these Bates numbers, but anyway it's the --
- 12 dated August 26th, 1997, and I guess it's a
- 13 deposition transcript.
- 14 Q. All right. Let me see if I can find the page --
- 15 A. Well no, that -- I mean you just asked me one
- 16 question, if I can give you the answer to that first.
- 17 Q. All right.
- 18 A. It's where he asks, whoever asks, somebody asks
- 19 Dr. Rowell: Do you have an opinion as to whether
- 20 cigarette smoking produces withdrawal symptoms on
- 21 sensation or efforts to stop.
- 22 Q. And his answer is?
- 23 A. I would say it does. And can you characterize
- 24 these as mild, moderate or severe? The withdrawal
- 25 symptoms I would say are relatively -- relatively

- 1 mild, which is just the answer I gave to you two and
- 2 a half hours ago.
- 3 Q. May I have that back, sir?
- 4 And then, sir, let me ask you this. You would
- 5 agree that your opinion about cigarette smoking not
- 6 being addictive is outside of the mainstream of
- 7 scientific thought; right?
- 8 A. You know, we've already said this depends how
- 9 you define "addiction." If you define it
- 10 classically, cigarette smoking is not addictive; if
- 11 you define it according to the latest surgeon general
- 12 report it is, and it all depends on your definition.
- 13 It's a semantic circle.
- 14 Q. Sir, isn't it true that one of the things that
- 15 Brown & Williamson considered was -- while you were
- 16 at Brown & Williamson was to develop a low-tar,
- 17 high-nicotine cigarette that could be marketed as an
- 18 addictive product in an ethical manner?
- 19 A. Well we certainly, as we've discussed before,
- 20 did a lot of work on trying to develop a, quote,
- 21 low-tar, normal nicotine, closed quote, cigarette in
- 22 line with recommendations of people like Dr. Russell
- 23 and Dr. Gori, G-O-R-I. We didn't succeed in doing
- 24 that but it was thought that, you know, that was a
- 25 suggestion of the health authorities and one we

- 1 pursued for a long time.
- 2 Q. Well sir, you attended a conference with
- 3 representatives -- other representatives from Brown &
- 4 Williamson and an advertising agency back in 1977 at
- 5 which the discussion of marketing an addictive
- 6 product in an ethical manner in the form of a
- 7 low-tar, high-nicotine cigarette was discussed,
- 8 didn't you, sir?
- 9 A. Well, you know, I can hardly remember a thing at
- 10 all I did in 1977. If you want to show me a
- 11 document, I can then work with you on it.
- 12 (Plaintiffs' Exhibit 4458 marked for
- identification.)
- 14 BY MS. WIVELL:
- 15 Q. Sir, showing you what's been marked as
- 16 Plaintiffs' Exhibit 4458, this is a document that
- 17 bears the Bates number 777125397 at the bottom;
- 18 right?
- 19 A. Right.
- 20 Q. And this is a memo of a meeting that you
- 21 attended as a representative of Brown & Williamson;
- 22 right?
- 23 A. That's what it says, yeah.
- 24 Q. And one of the purposes of this meeting was to
- 25 discuss a low-tar cigarette; right?

- 1 A. Well, I guess your guessing is not unreasonable
- 2 that "LT" means low tar, but I'm not quite sure what
- 3 the "S" means.
- 4 Q. All right. Well sir, if we turn to the second
- 5 page of Exhibit 4458 --
- 6 A. Okay.
- 7 Q. -- there is a goals or wish list that came out
- 8 of this meeting; right?
- 9 A. Yeah.
- 10 Q. And if we turn to the second-to-the-last item on
- 11 that wish list, it says -- one of the wishes was to
- 12 "market an ADDICTIVE PRODUCT in an ETHICAL MANNER";
- 13 right?
- 14 A. Yeah, this is a goal and wish of P-A-T which I
- 15 presume is -- I don't know who it is.
- 16 Q. Well sir, you attended this meeting; right?
- 17 A. Oh, yeah.
- 18 Q. All right. And --
- 19 A. I guess, yeah.
- 20 Q. -- among the wish list items there is to have a
- 21 cigarette that would have free nicotine as opposed to
- 22 bound nicotine; right?
- 23 A. Yeah.
- MS. WIVELL: I have nothing further.
- 25 EXAMINATION

- 1 BY MR. McCORMICK:
- 2 Q. Is Exhibit 4858 [sic] a Brown & Williamson or a
- 3 BATCo document, or is it a document of the Hawkins
- 4 McCain & Blumenthal, Inc. advertising company?
- 5 (Discussion off the stenographic record.)
- 6 Q. I'm sorry, Exhibit 4458.
- 7 A. I'm sorry, are you asking me?
- 8 Q. Yes.
- 9 A. As far as I can tell it's some conference report
- 10 of an advertising agency.
- MR. McCORMICK: That's all I have.
- 12 EXAMINATION
- 13 BY MS. WIVELL:
- 14 Q. And this conference report of the advertising
- 15 agency, Exhibit 4458, is a summary of a meeting that
- 16 took place that you attended; right?
- 17 A. Apparently so, yeah.
- 18 Q. And --
- 19 A. I'll tell you it's --
- 20 Q. This document came out of the files of Brown &
- 21 Williamson, sir, didn't it?
- 22 A. Yeah, I'm not disputing that. I was trying to
- 23 -- I was hesitating. I was trying to answer because
- 24 it's -- I mean, I haven't looked at all of it and I
- 25 guess you don't want to either, but it seems to be

- 1 all sorts of bits and pieces and so I mean they're
- 2 talking about creative groups in New York, and names
- 3 for premium cigarettes and so it doesn't look like
- 4 one meeting, it looks like a compilation of stuff and
- 5 I don't -- I can't help you any more in any context.
- 6 Q. Well sir, at least according to the cover memo
- 7 of Exhibit 4458, at the meeting that you attended the
- 8 pharmacological effects of an LTS product were
- 9 discussed; right?
- 10 A. Well, you know, that's -- that's what this says
- 11 and I can't debate or dispute it. It's an
- 12 advertising agency conference report.
- 13 Q. Do you have any recollection of the substance of
- 14 the subjects that was discussed at the meeting?
- 15 A. I wouldn't know McCain, Hawkins or Blumenthal if
- 16 I bumped into them in the street.
- MS. WIVELL: I have nothing further.
- MR. McCORMICK: Nothing further.
- 19 THE REPORTER: Off the record, please.
- 20 (Deposition concluded at approximately
- 21 5:25 p.m.)

22

23

24

25

CERTIFICATE

1

2	I, Debby J. Campeau, hereby certify that I
3	am qualified as a verbatim shorthand reporter; that I
4	took in stenographic shorthand the testimony of M.
5	LANCE REYNOLDS at the time and place aforesaid; and
6	that the foregoing transcript consisting of 139 pages
7	is a true and correct, full and complete
8	transcription of said shorthand notes, to the best of
9	my ability.
10	Dated at Lino Lakes, Minnesota, this 1st
11	day of October, 1997.
12	
13	
14	
15	DEBBY J. CAMPEAU, RPR
16	Notary Public
17	
18	
19	
20	
21	
22	
23	
24	
25	

1	S I G N A T U R E P A G E
2	I, M. LANCE REYNOLDS, the deponent, hereby
3	certify that I have read the foregoing transcript,
4	consisting of 139 pages, and that said transcript is
5	a true and correct, full and complete transcription
6	of my deposition, except per the attached
7	corrections, if any.
8	
9	(Please check one.)
10	Yes, changes were made per the attached
11	(#) Signature Page Addendums.
12	
13	I have made no changes.
14	
15	
16	
17	
18	
19	
20	M. LANCE REYNOLDS
21	Deponent
22	Sworn and subscribed to before me this day
23	of , 199
24	Notary Public
25	My commission expires: (DJC)
	STIREWALT & ASSOCIATES

P.O. BOX 18188, MINNEAPOLIS, MN 55418 1-800-553-1953